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Chapter 1
1.1 An Introduction to light
1.1.1 Light in a historical perspective
Light is all around us and is the most important requisite to result in the creation 
of life. This has been known from the early beginnings of human life. The ancient 
Egyptians, Sumerians and Aztecs have worshipped the sun as the bringer of life 
and as the God of gods. Even the Bible starts with one of the best-known religious 
statements after the creation of heavens and earth: "And God said: Let there be light 
and there was light" (Genesis 1:3), after which God creates life on earth.
As the most important life giving substance, ancient people started to attribute healing 
powers to the sun, like the ancient Egyptian priests and healers, who sometimes tried 
to increase these healing powers with a herb (Ammi majus Linnaeus) grown on the 
banks of the river Nile, nowadays known to contain a photoactive substance called 
Psoralen (1400 B.C.). Even the ancient Chinese used photoactive herbs like Bu Gu 
Zi (fructus Psoralea Corylifoliae). The Greek were the first to introduce the term 
heliotherapy as the first kind of phototherapy. Hippocrates wrote extensively about 
the healing powers of the sun in his Corpus Hippocraticum (460-375 B.C.). There are 
numerous accounts of the suns healing properties in religious and medical texts and 
literature (1-4).
Already during the Roman days, skin colour became the visible definer to separate 
the (ruling) upper class from the (working) plebs. The paler one's skin, the higher 
one's class. During those days, people used chalk to whiten their skin and during 
the mid1 0 th century this was replaced by arsenic, both with deadly side effects due 
to lead or arsenic poisoning. Nowadays, in Asia men prefer women with the fairest 
skin, while in the Western world since the 20th century a bronzed colour is preferred 
(5,6).
It was not until the end of the 19th century when western medical doctors started to use 
sun exposure for its healing powers in special medical facilities called sanatoria for 
the treatment of tuberculosis of the skin (1,7). It was soon recognised that only certain 
parts of the light spectrum had beneficial effects on several chronic skin diseases like 
psoriasis and eczema and that the lack of sun exposure could lead to deficient bone 
development (rickets) as experienced during the industrial revolution around 1800
(1). With the invention of electricity and light bulbs and eventually specialised lamps 
with specific emission spectra, artificial light exposure was introduced as a medical 
therapy. Several diseases and natural and chemical substances were also recognised, 
where (combination with) light exposure had acute hazardous effects on the skin, 
like bulleous reactions in patients with porphyrias, or contact phototoxicity reactions 
with tar and plants like Hogweed and St. John's worth. It took more decennia 
before eventually in the 1970-80's the link between several kinds of skin cancer
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and sun exposure was recognised, although Unna had already described a possible 
relationship in 1894 (4,8).
As ultraviolet light has major implications for our skin and body, it is of the utmost 
importance to gain understanding in photobiological mechanisms. First, we have to 
discuss some basic physical concepts.
1.1.2 The nature of light
Light represents only a small part of the electromagnetic spectrum, ranging from 
radioactive radiation on the one side to radio and television waves on the other side. 
Light is somewhere in the middle and is usually divided in infrared and visible light, 
UVA, UVB and UVC as shown in figure 1-1. UVB is defined as the electromagnetic 
spectrum ranging from 290 or to 320 nm. UVA ranges from 320 to 400 nm and visible 
light ranges from approx. 400 to 750 nm wavelength (9).
290 320 
UVC UVB UVA
400
Visible Light
750
IR
Literature is not always consistent on the term light. Sometimes it only refers to 
visible light (so UV and IR are referred to as radiation) and sometimes it spans the 
whole of the above-mentioned spectrum.
The photobiological action spectrum of light on the skin depends on the available 
photoactive substances, the amount of energy conveyed by the light and the 
penetration depth.
Skin penetration depth of light depends on wavelength and reflectance. The longer the 
wavelength the deeper the penetration and the larger the change in refractive index 
between air, skin and tissues, the more light is reflected. As a real life example of this 
concept one can hold a strong flashlight against the skin of the cheek or between one’s 
thumb and forefinger. The refractive index change between air (nD = 1.0) and stratum 
corneum (nD ~ 1.55) is quite large, so part of the light is already reflected. The part 
that will penetrate the skin is red, because this is the light that can penetrate the skin 
this far (approximately 0.5-1 cm) (10).
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One of the most important concepts of light is described with the following formula:
E ht = h.v (with: h = Planck constant) = 1 9 8  1° - ' 9 watt seconds 
p wavelength in nanometers
This implies that the longer the wavelength the less energy each photon (light particle) 
has. So a photon of UVB has more energy than UVA or red light (11).
The ozone layer keeps UVC out of our atmosphere, so only UVA, UVB, visible 
light and infrared light penetrate our atmosphere. It is this spectrum that exerts the 
photobiological effects on the human skin. When this high energetic light penetrates 
the skin it encounters a magnitude of molecules on its way through the skin. Several 
photoactive molecules (chromophores) like bilirubin, haem and DNA can absorb 
these energies and shift from their ground state to states of higher energy (12-15). 
When photonic energy is absorbed, electrons are promoted to previous unoccupied 
higher energy orbits around the atomic core. Depending on the amount of photonic 
energy the excited state will be singlet (less energy) or triplet (more energy). Singlet 
excited states are more unstable than triplet excited states, but both desperately want 
to return to their ground state. This is only possible when electrons return to their 
original orbit around the atomic core, by transferring their excessive energy to the 
surrounding molecules as photonic energy (fluorescence), heat or by interacting with 
other molecules. Interaction with other molecules will usually result in arrays of 
biochemical chain reactions (16).
1.2 Photobiological effects of light
Photobiological effects depend not only on the wavelength, the amount of energy 
conveyed by the light and the depth of the penetration, but also on the type of 
exposure (repetitive or single).
Clinically the following acute effects can be observed:
► Acute excessive exposure results in sunburn, usually experienced as transitional 
painful erythematous skin with shedding of the upper epidermal layers (17).
► Repetitive exposure to lower dosages results in transitional epidermal 
thickening, hyperpigmentation and dryness of the exposed skin.
Chronic exposure results in the following clinical features:
► Wrinkling and thickening of the skin.
► Shift in pigmentation (freckling, lentigines, irregular hyper- and 
depigmentation).
► Photocarcinogenesis (actinic keratosis, M. Bowen, basal cell carcinoma and 
squamous cell carcinoma) (17).
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All these effects can be interpreted as immunological effects and photodamage.
1.2.1 Immunological effects
The skin provides one of the most important defences against invading micro­
organisms and malignant transformed cells. This is accomplished by an intricate 
system of transient and resident immunological active cells. Transient cells are 
predominantly circulating T-lymphocytes, polymorphonuclear granulocytes, 
monocytes and macrophages and are usually described with the term Skin 
Associated Lymphoid Tissue (SALT). Resident immune cells comprise antigen 
presenting Langerhans cells (LC's), immunomodulatory keratinocytes, mast cells 
and endothelial cells.
The amount of energy, wavelength and the type of exposure determine the 
immunomodulatory effects of light exposure.
UVB
Acute excessive single or repetitive exposure to UVB results in sunburn. Sunburn 
is immunologically characterised as immunoactivation with initially an influx 
of polymorphonuclear leukocytes up to 14 hours post exposure, followed by a 
predominantly mononuclear perivascular inflammatory infiltrate which peaks at 
about 14-21 hours, but also with a reduction of the density of epidermal LC's after 24 
hours. Mast cells degranulate within 3-5 hours after exposure eventually leading to 
depletion (18,19).
Several studies have shown that chronic and repetitive exposures of UVB result in 
suppression of type IV hypersensitivity reactions by reducing the amount of LC's in 
the epidermis. Ear swelling of mice sensitised to a certain hapten was significantly 
less after re-exposure to the hapten after repetitive UVB exposure compared to no 
or only a single or repetitive UVB exposure (20,21). Several authors report that IL-
1 production and MHC class II expression are also reduced, thereby increasing this 
immunosuppressive effect (22,23).
Prolonged exposure (> 6  weeks) to UVB decreases the number of circulating T- 
lymphocytes and monocytes, while increasing the number of T-lymphocytes in 
peripheral lymph nodes. This may be explained by the fact that the expression of 
adhesion molecules like ICAM-1, which play an important role in lymphocyte 
homing, is reduced. Cytokine production in the skin is modulated by UVB irradiation. 
E.g. TNF-a, a strong pro-inflammatory cytokine, is up regulated after UVB exposure, 
and can also impair contact hypersensitivity reactions (CHS) (24).
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UVA
In contrast to UVB, exposure to UVA generally does not result in erythema and 
sunburn. Although several studies seem to contradict the previous statement, 
the effects seen in those studies are considered to be at least partly the result of 
incomplete shielding of the UVB and UVC output of the irradiation source (19,25­
27). With no distinct erythema and sunburn, one could assume that UVA has no 
immunomodulatory effects at all, however UVA exposure does result in some 
inflammation and immunosuppression. The inflammatory response is marked by 
some perivascular inflammatory infiltrate, consisting of neutrophilic granulocytes 
influx 3 hours post irradiation, and a predominantly lymphocytic infiltration. LC's 
count reduces significantly too (19,22,26). This inflammatory response on UVA 
is most likely mediated by oxidative damage. For example glutathione, a potent 
endogenous radical scavenger, inhibits several immunomodulatory functions of UVA 
radiation in a dose dependent manner (28,29). It is assumed that products of oxidative 
damage can induce the production of immunomodulatory cytokines like IL-12 
(30,31). Most studies on the immunomodulatory effects of UVB have concentrated 
on CHS reactions. So far no comparative studies between UVA and UVB have been 
performed on this subject.
1.2.2 Photodamage
Photodamage can be divided in 
photocarcinogenesis and photoageing. 
Photocarcinogenesis is a complex mechanism 
of UV induced DNA damage, impaired repair 
mechanisms and failure of the skin immune 
system to detect malignant cells.
Photocarcinogenesis
When UV penetrates into the skin it reacts 
with photoreactive molecules in the skin called 
chromophores. One of these chromophores is 
DNA. Direct (UVB induced) DNA photoproducts 
are typically cyclobutane pyrimidine dimers 
(CPD), which can be thymine (T-T), cytosine 
(C-C) dimers or thymine-cytosine or cytosine- 
thymine bonds in keratinocytes, with a strong 
Figure 1-2: p53 repair mechanism preference for thymine dimers (32,33).
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Indirect photoproducts are produced by interaction with reactive oxygen species 
(ROS) and consist mainly of DNA strand breaks and protein cross-linking (12,13). 
Normally, when DNA damage occurs, the cell cycle is halted to give time to repair 
the damage. One of the main factors involved is p53, a tumour suppressor gene, 
which can result in a G1 cell cycle arrest following activation (34). During this 
cell cycle arrest, damage is evaluated and repaired, which results in increased cell 
survival, or when the damage is regarded too extensive, the cell is terminated by 
apoptosis (35-38). Nuclear excision repair enzymes, like p16, play a major role in 
repair processes (38). Figure 1-2 summarises the photobiological effects of UV 
on keratinocytes. Repair can be complete or incomplete. Incomplete repair results 
in living keratinocytes with damaged DNA, which can result in uncontrolled cell 
growth (38). Cell surface antigens are absent or changed, which trigger the skin 
immune system to remove these cells. As described in paragraph 1.2.1 the immune 
system is impaired in skin following chronic exposure to UV light. This increases the 
risk of photocarcinogenesis (8,39-41).
Photoageing
Photoageing is the process of induction of enzyme systems resulting in increased 
destruction and remodelling of the intercellular matrix leading to decreased elastin 
and collagen content (42,43). This process gives the skin a wrinkled look. Other 
processes that takes place in photoageing are changes in pigmentation and atrophy of 
the skin (44).
Chemical reaction with oxygen containing molecules result in the formation of 
superoxide anion radicals (O2-) and singlet oxygen 0O2). These reactive oxygen 
species are highly unstable and react with surrounding molecules, thereby activating 
biochemical cascades or damaging structures like collagen. Wlaschek et al. showed 
that 1O2 induces the production of collagenase-mRNA (44). Furthermore, ROS has 
the capacity to strongly inhibit tissue inhibitors of metalloproteinases (TIMP's) (45). 
UVB activates MAP-kinases like c-Jun amino-terminal kinase (JNK), p38 en ERK 
via lipidperoxidation products. Subsequent phosphorylation of c-Jun proteins and 
combination with c-Fos proteins produce activator protein (AP)-1 complexes. 
Binding with the AP-1 response element (AP-RE) induces the transcription of 
several MMPs (46). MMPs are extracellular matrix degrading proteins (see table 1­
1) and form, combined with their inhibitors (TIMP's), an intricate extracellular matrix 
remodelling system.
Prolonged and excessive degradation of the extracellular matrix eventually results in 
fragmentation of collagen and elastin fibres and thus in wrinkled skin.
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Table 1-1: Overview of currently known MMPs and substrates (adapted from McCawley et 
al. (47))
MMP subgroup MMP number Synonym Matrix substrate
Collagenases MMP-1 collagenase-1 collagen I, II, III, VII, X, gelatin, entactin, aggrecan,
MMP-8 collagenase-2 tenascin.
MMP-13 collagenase-3
Stromelysines MMP-3 stromelysine-1 proteoglycans, laminins, fibronectin, gelatin, collagen.
MMP-10 stromelysine-2 III/IV/V/IX/X/XI, fibrin / fibrinogen, entactin, tenascin, 
vitronectin.
MMP-11 stromelysine-3 laminin, fibronectin, aggrecan.
Gelatinases MMP-2 gelatinase A gelatin, elastin, fibronectin, collagen I, IV, V, VII, X, XI,
MMP-9 gelatinase B laminin, aggrecan, vitronectin.
Minimal
domain
MMP-7 matrilysine proteoglycans, laminins, fibronectin, gelatin, collagen. 
III/IV/V/IX/X/XI, fibrin / fibrinogen, entactin, tenascin, 
vitronectin
MMP-26 matrilysine-2 / 
endometase
gelatin, collagen IV, fibronectin, fibrinogen
Membrane MMP-14 M T1-MMP gelatin, fibronectin, vitronectin, collagen, aggrecan.
associated MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-24 M T5-MMP
MMP-17 MT4-MMP gelatin.
MMP-25 MT6-MMP gelatin, collagen IV, fibrin, fibronectin, laminin-1.
MMP-23 gelatin.
Other MMPs MMP-12 metalloelastase elastin, fibronectin, fibrin/fibrinogen, laminin, 
proteoglycan.
MMP-19 RA SI gelatin, tenascin, fibronectin, collagen IV, laminin, 
entactin, fibrin/fibrinogen, aggrecan.
MMP-20 enamelysin COMP.
MMP-28 epilysin amelogenin, aggrecan, COMP.
1.3 Immunosuppression and responses to ultraviolet radiation
1.3.1 General aspects
The immune system is of relevance in acute and chronic effects of ultraviolet 
radiation.
Acute effects of UV radiation compromise the inflammatory responses, characterised 
by pain, erythema and blistering (17,19,41). Cyclooxygenase inhibitors and 
corticosteroids suppress these responses (48-51). On the other hand, systemic 
immunosuppressive treatments may counteract the "off-switch" of UV-induced 
inflammation. Indeed, it is important that during methotrexate or cyclosporin A 
treatment patients should be warned for prolonged UV induced burns. Therefore, in
16
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patients with immunosuppressive treatments sun exposure should be reduced. 
Chronic effects of ultraviolet light combined with immunosuppression comprise a 
vast increase of the number of actinic keratosis, with increased development of basal 
cell carcinoma and squamous cell carcinomas (non-melanoma skin cancer) (52,53). 
The combination of UV induced DNA damage and (UV) immunosuppression is 
likely to result in photocarcinogenesis. This is particularly noticeable in patients with 
impaired or deficient DNA repair, like patients with xeroderma pigmentosa, but also 
in renal transplant patients with long-term immunosuppressive medication (52,54­
56). In all these patients highly increased numbers of skin cancer develop on UV 
exposed skin, like face, hands, fore-arms, shoulders, lower-legs and feet.
1.3.2 Single target therapies in chronic inflammatory diseases
In recent years pharmaceutical companies are more and more focusing on single 
target therapies for chronic inflammatory T-cell mediated diseases such as 
psoriasis and rheumatoid arthritis as possibilities arise to create specific antibodies 
against proteins and receptors which are relevant in the pathogenesis. Selective 
immunomodulation may increase safety with regard to infections and carcinogenesis. 
Several antibodies have been engineered against T-lymphocyte surface molecules 
such as LFA3TIP (Alefacept, Amevive®, Biogen), which blocks the co-stimulatory 
pathway between Antigen Presenting Cells and CD2 on T-lymphocytes, IDEC-114 
(IDEC Pharmaceuticals), which blocks the co-stimulatory pathway CD80-CD28 on 
antigen presenting cells and T-lymphocytes, and anti-CD4 antibodies (OKTcdr4a, 
Immunoclone, Johnson & Johnson) (57,58). Other manufacturers focus on 
intracellular T-lymphocyte signalling blockers, such as Pimecrolimus® (SDZ ASM 
81, Novartis) and Tacrolimus (FK506) (59,60). Clinical and laboratory studies have 
shown that these therapies have promising results in the treatment of e.g. psoriasis. 
Recently anti-TNF-a and TNF-a receptor constructs have been registered for the 
treatment of rheumatoid arthritis (RA), juvenile chronic arthritis and Crohn's disease 
(61,62). Several placebo-controlled studies have also reported clinical efficacy 
of these compounds in the treatment of psoriasis (63-65). The major concerns of 
immunosuppressive treatments are infections and carcinogenesis. In this thesis the 
question is addressed whether an anti-TNF-a approach influences photodamage and 
photocarcinogenesis. As presented in section 1.2.1 TNF-a plays an important role in 
UVB induced inflammation and apoptosis. Chapter 3 will discuss the effects of anti- 
TNF-a on these mechanisms.
17
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1.4 Phototherapy
1.4.1 General aspects
Several skin disorders can be treated with phototherapy (UVB) or photochemotherapy 
(PUVA). PUVA is the combination of UVA with a systemic or topical application of 
a psoralen (P). In particular psoriasis, affecting 2% of the world population, may be 
treated with phototherapy after topical treatments have failed to be effective (6 6 ). In 
recalcitrant atopic dermatitis, narrow band UVB (311 nm) and high dose UVA1 have 
become treatment options. Photo (chemo)therapy can be given as a monotherapy 
or combination therapy (67,68). The combination of photo (chemo)therapy with 
systemic retinoids is a highly effective approach for patients with cutaneous T-cell 
lymphoma and patients with sever psoriasis (69,70).
1.4.2 Vitiligo, a neglected area in UVB phototherapy
Vitiligo is a chronic skin disease characterised by depigmented areas on the skin 
due to the absence of melanocytes (3). Descriptions are found in several ancient and 
classic texts, e.g. the Atharva Veda, one of the most important scriptures in Indian 
history (dated 1500 BC), relates of king Pandu, who was covered by white spots 
(kilas or palita). Due to visual similarities, vitiligo patients were often mistakenly 
treated and outcasted as lepers.
The aetiology and pathogenesis of vitiligo are still unknown. Based on clinical 
findings in patients several theories have been proposed: the genetic theory as 25­
30% of the patients have affected family members, the auto-immune theory as up to 
77% of the patients have auto-antibodies against melanocytes or one or more other 
auto-immune diseases, the neurogenic theory for segmental vitiligo, which follows 
dermatomes, the melanocytes self-destruction theory as radical scavenger deficiencies 
have been detected in several patients, and last but not least the convergence theory 
which combine all previous mentioned theories (71). With advancing knowledge 
of melanogenesis and melanocyte biochemistry and physiology, several new 
theories have been suggested. All these new theories share the common idea that 
a deficiency in one of the biochemical essential compounds plays a role in the 
pathogenesis of vitiligo, like pseudocatalase, calciumchlorid, vitamin B12 and folic 
acid (72-74). These theories are based on the fact that in some patients a deficiency 
of pseudocatalase and/or calciumchlorid has been detected in or surrounding vitiligo 
lesions. Overall vitamin B12 and folic acid deficiencies in patients have not been 
reported. In several large groups of vitiligo patients serum concentrations were 
however low (72,75). Some authors speculate that this deficiency could be a common 
feature of vitiligo (72,75).
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Vitiligo is a disease with minimal physical disabilities. Melanocytes have an important 
function in protecting the skin against the deleterious effects of UV irradiation, by 
producing melanosomes, which absorb most of the energy of UV irradiation and 
play an important part in determining skin colour (76). Vitiligo lesions are thus prone 
for sunburn, however there is still some controversy whether such also results in 
photocarcinogenesis and skin ageing (77-80). Several authors suggest that vitiligo 
patients are protected against photocarcinogenesis as epidemiological studies have 
shown that the incidence of skin malignancies is less in vitiligo patients and for this 
reason promote the almost unlimited use of phototherapy as a repigmenting therapy 
(78). It is however possible that because patients are more prone to sunburn they 
avoid sun exposure more, thus minimising the chance of photocarcinogenesis. 
Psychosocial disabilities play an important role in vitiligo patients, especially in 
representative occupations and dark pigmented races (81,82). Treatment thus focuses 
on reducing the contrast between pigmented and depigmented skin. There are several 
options available. The easiest and most used option is to cover the lesions with 
clothing or camouflaging makeup. Some people tattoo their lesions. These options 
do not result in repigmentation. Repigmenting therapies are divided in surgical 
transplantation or phototherapy.
The following transplantation techniques can be used:
► Minigrafting: punch biopsies are taken from normal pigmented skin and 
transplanted in depigmented lesions.
► Split-skin grafting: sheets of normal pigmented epidermal skin are transplanted 
in depigmented lesions.
► Suction blister roof grafting: the roofs of artificially created suction blisters are 
transplanted in depigmented lesions.
► Cultured cell grafting: melanocytes are extracted from skin punch biopsies 
and cultured in a laboratory. These are harvested and sowed in depigmented 
lesions.
Transplantation techniques are often combined with phototherapy to stimulate the 
growth of the transplanted melanocytes (71,83,84).
Psoralen UVA (PUVA) phototherapy has been used to treat vitiligo since the ancient 
Egyptians (3). At this moment PUVA is the main treatment for vitiligo in most countries 
and is being regarded as the most effective repigmenting therapy, sometimes applied 
as topical photochemotherapy (bath or cream PUVA) but mostly used as systemic 
photochemotherapy (oral PUVA). The exact mechanism of repigmentation under 
photochemotherapy is still unknown. Several authors suggest that by decreasing the 
amount of LC's and immunosuppression the autoimmune phenomenon can be halted, 
and thereby changing the balance of de-/repigmentation and thus allowing the skin to 
repigment again (3,85).
Photochemotherapy is generally considered a modified phototoxic treatment with
19
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hazardous side-effects. Recent studies have shown that photochemotherapy with 
treatment schedules with over 2 0 0  exposures significantly enhance the risk of skin 
cancer (8 6 -8 8 ). It is however still unclear whether vitiligo patients are more or less 
prone to photocarcinogenesis.
Recently, narrow band UVB phototherapy has been designated as a safe and effective 
way to treat vitiligo patients (89). However, large controlled studies on the efficacy of 
narrow band UVB have not been performed yet. Furthermore, several authors suggest 
that the addition of vitamin B12 and folic acid may enhance photo-repigmentation 
(72,90). Chapter 4 will take a closer look at this new treatment in terms of efficacy 
and quality of life and investigates the claim of enhanced photo-repigmentation with 
the addition of vitamin B12 and folic acid.
1.5 Aims
The aims of this thesis are:
I. Further elucidation of the photobiological effects, in particular regarding 
photodamage of UVA, broadband UVB, narrowband UVB and visible light.
II. To find out to what extent anti-TNF-a treatment modulates the response to 
UVB challenge
III. To find out the clinical efficacy of narrow UVB treatment in vitiligo and the 
impact of this treatment on quality of life.
Questions:
I.a What is the difference with respect to photodamage comparing UVA and 
UVB?
I.b What is the difference regarding photodamage comparing broad band and 
narrow band UVB?
I.c Is visible light capable in inducing photodamage?
II.a What is the effect of anti-TNF-a treatment on the photobiological effect after a 
single broad band UVB challenge
III.a Is narrow band UVB an effective treatment for vitiligo vulgaris?
III.b Does the addition of vitamin B12 and folic acid modulate the efficacy of 
narrow band UVB phototherapy in the treatment of vitiligo vulgaris?
III.c Does long-term narrow band UVB phototherapy for vitiligo vulgaris influence 
the quality of life?
20
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1.6 Methodology
1.6.1 UV and visible light challenge models
To address questions 1.1 up to 2.1 several UV and 
visible light challenge models were used.
All UV irradiations were performed with Waldmann 
UV phototherapy units (Waldmann 7001K, Waldmann 
Medizintechnik, Villingen-Schwenningen, Germany) 
equipped with broadband UVB (Philips UV21, Philips 
B.V, Eindhoven, the Netherlands), narrow band UVB 
(Phillips TL-01) or UVA (Philips UV6 ) lamps (see 
figure 1-3). Each lamp has its' own emission spectra 
and wave distribution. Figures 1-4 to 1-6 show the 
emission spectra of these lamps and the relative wave 
distribution.
cabin
Figure 1-4: UV21 Broad band UVB distribution
Figure 1-5: TL-01 Narrow band UVB Figure 1-6: UV6 Broad Band UVA
distribution Distribution
All UV challenge models used single dose irradiation of 2-3 Minimal Erythema
Doses (MED) with punch biopsies of unirradiated skin and irradiated skin at several
time points (usually 4, 7, 24 or 48 hours) post exposure.
Minimal Erythema Dose was defined as just perceptible erythema 24 hour after
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irradiation and was assessed by irradiating six circular areas of 2.5 cm in diameter 
located horizontally just above the buttocks with an incremental dosage scheme
(91).
Table 1-2: Fitzpatrick’s Skintypes
Skin type Description
I Always burns easily, never tans
II Always burns easily, tans minimally
III Burns moderately, tans gradually and uniformly (light brown)
IV Burns minimally, always tans well (moderately brown)
V Rarely burns, tans profusely (dark brown)
VI Never burns, deeply pigmented
Depending on skin types, as defined by Fitzpatrick (see table 1-2), and the used UV 
source an appropriate dosage scheme was selected (see table 1-3) (92,93). After 
MED assessment, the skin on the unexposed buttocks was irradiated once with an 
appropriate dose set by the biological response (i.e. dose related to the individual
m e d ).
Table 1- 3: MED Dosage schemes according to skintype
Skin type MED dosage scheme 
Broad band UVB
I-II 0.05-0.09-0.12-0.16-0.20-0.27 J/cm2 
III-IV 0.05-0.10-0.15-0.20-0.30-0.40 J/cm2
Narrow band UVB
I-II 0.50-0.70-0.90-1.10-1.30-1.50 J/cm2 
III-IV 0.50-0.70-0.90-1.10-1.30-1.50 J/cm2
High dose visible light has been given in repeated 
exposures with a Waldmann PDT 1200 L (Waldmann 
Medizintechnik, Villingen-Schwenningen, Germany, 
see figure 1-6) equipped with a Philips 1200 MSR metal 
halogen lamp (Philips B.V, Eindhoven, the Netherlands), 
which has an emission spectrum of 560-780 nm after 
filtering with the build-in dichroic cut-off filters (DT Rot 
and Calflex-3000, Balzers Optik, Nurnberg, Germany). 
Irradiations are also given on the buttocks, as these areas 
of the skin have had only minimal exposure to light.
Figure 1-7: Waldmann 
PDT 1200 Unit
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After irradiation, biopsies were taken at predefined time points.
Whether UVB, UVA or visible light was given, in all cases the surrounding skin was 
protected with light impenetrable cloth.
1.6.2 Immunohistochemical analysis 
Processing of biopsies
Punch biopsies (Stieffel, Offenbach am Main, Germany) were taken with 1% 
Xylocain and Adrenalin anesthesia and, depending on the immunohistochemical 
staining, embedded in Tissue-Tec OCT compound (Miles Scientific, Naperville, 
USA) and snap frozen in liquid nitrogen or embedded in paraffin after a 4-hour 
fixation in formaldehyde.
All biopsies were cut in 6-7 |im thick slides and stained with H & E or with 
immunohistochemical markers and counter stained with Mayer's haematoxylin 
(Sigma, St. Louis MO, USA).
H & E stained slides were assessed for sunburn cells 
(apoptosis), perinuclear vacuolisation and perivascular 
inflammation. Sunburn cells are defined as epidermal cells 
with pyknotic nuclei and a strong eosinophilic cytoplasm. 
The sunburn cell is a specific marker for apoptotic 
keratinocytes. Apoptotic keratinocytes are a characteristic 
of UV irradiated skin. Sunburn cells were quantified and 
scored as the amount of positive cells in the epidermis. 
Inflammation was scored on a semi-quantitative scale (0: 
none present, 1: minimal, 2: moderate and 3: pronounced 
amount/staining) (94,95).
Immunohistochemical analysis
The immunohistochemical antibodies, mentioned in table 1-4, were used to asses 
photodamage and photo ageing. Most markers were stained using the Avidin-Biotin 
Complex amplification technique. Only Langerhans cell staining was performed 
with the peroxidase-anti-peroxidase amplification technique. Both techniques are 
described more in detail in the following chapters.
Epidermal nuclear stainings like p53, c-jun and p16 were scored as amount of positive 
cells/mm length or per 1000 cells. A similar approach was used for the cytoplasmatic
Histological analysis
Figure 1-8: Sunburn cells
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stainings T6 , and Melan A. Inflammatory infiltrate was subdivided in lymphocytes, 
polymorphonuclear leukocytes and monocytes/macrophages. These groups were 
scored as the percentage of positive cells in the perivascular infiltrate on a validated 
semi-quantitative scale as reported before (0 = 0%, 1= 1-24%, 2 = 25-49%, 3 = 50­
74%, 4 =75-100%).
Table 1-4: Overview of used antibodies and dilutions
Antibody Target Dilution
Monoclonal murine anti-human p53 protein 
(Dakopatts, Glostrup, Denmark)
(wild type and mutant) p53 
protein
1:200
PhosphoPlus c-Jun (Ser63) II Antibody kit 
(New England Biolabs Inc., Beverly, MA, USA)
phosphorylation on point 63 
of c-Jun
1:50
Monoclonal murine anti-elastin antibody 
(Sigma, St Louis, USA)
Elastin fibers 1:500
Ab-4 Mouse anti-human p16 
(Neomarkers, Fremont, USA)
P16 1:100
Monoclonal murine anti-human MMP-1 
(Oncogene, San Diego, USA)
MMP-1 1:15
DAKO T-11
(Dakopatts, Copenhagen, Denmark)
T-lymphocytes 1:100
DAKO T6
(Dakopatts, Copenhagen, Denmark)
Langerhans cells 1:100
DAKO anti-elastase 
(Dakopatts, Copenhagen, Denmark)
PMN's 1:100
WT14
(UMCN, Nijmegen, the Netherlands)
Monocytes/macrophages 1:100
Monoclonal murine anti-human Melan A 
(MART-1, Oncogene, San Diego, USA)
Melanocytes 1:50
1.6.3 Studies during anti-TNF-a induced immunosuppression
Recently, adalimumab, a fully human chimeric anti-TNF-a antibody (Knoll AG, 
Ludwigshafen, Germany) has been introduced for the treatment of rheumatoid arthritis 
(96). The antibody is administered subcutaneously and maximum clinical efficacy 
can be observed 2 weeks after the first administration. In this thesis the effects of the 
first subcutaneous administration of anti-TNF-a (0.5 mg/kg) on the UVB response 
are studied. Minimal erythema dose assessment was performed before and 2 weeks 
after the administration of the antibody. Biopsies were taken from unirradiated and
2 MED irradiated skin before and 2 weeks after administration of the antibody for 
immunohistochemical analysis.
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1.6.4 Studies in Vitiligo
In order to answer the questions regarding phototherapy in vitiligo, a clinical trial was 
performed in which long term stable vitiligo patients were randomised in two groups, 
one with vitamin B12 and folic acid twice daily and one without. All patients were 
irradiated with narrow band thrice weekly.
Clinical Assessment
There is no standardised and validated scoring method for evaluating the clinical 
efficacy of therapies in vitiligo like the Psoriasis Area Severity Index (PASI) for 
psoriasis treatment evaluation. Several studies have reported their own systems for 
scoring repigmentation during treatment (97-99). These scoring methods have their 
limitations as they only evaluate the overall final result as a percentage on a x-point 
scale. The following methods are the most used.
► If overall repigmentation is more than 80%, these patients are scored as 
complete repigmentation.
► Other scores divide the scale in 3 (1 = <30%, 2 =30-60%, 3= 60-100%). 
However, the following aspects of vitiligo seriously limit the validity of these 
approaches. The most important mode of repigmentation is the perifollicular 
repigmentation, which causes substantial inter-observer variation. Furthermore, 
there is a lot of variability between and within vitiligo patients with respect to body 
region. It is generally known that specific regions do pigment easily while others 
do not repigment at all. Therefore, overall scores do not provide clinical relevant 
information. Surprisingly, there is no study available, which evaluates repigmentation 
per region. Although quality of life scoring during treatment is a common aspect of 
e.g. psoriasis or atopic dermatitis treatment evaluation, this has never been reported 
in vitiligo patients, although it is known that vitiligo patient generally do suffer from 
the psychosocial implications of their disease.
To overcome the mentioned shortcomings we evaluated repigmentation per region 
during and at the end of the study and evaluated the quality of life after treatment.
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Chapter 2
2.1 The time course of the in vivo response to oxidative stress 
following UVA and UVB exposure
2.1.1 Abstract
Background Ultraviolet radiation induces a range of photobiological effects, such 
as an inflammatory response, photodamage and photoageing. It has long been 
hypothesised that UVA exerts it effects through oxidative processes, while UVB 
directly damages cell structures.
Objectives The aim of the present study is to elucidate the differences and possible 
relationships between the time course of UVA and UVB induced photodamage, 
inflammation and oxidative damage in vivo.
Patients/Methods Fourteen volunteers were challenged with one MED UVB or 60 
J/cm2 UVA on the lower back. At several successive time points biopsies, tapestrips 
and ethanol extractions were collected from irradiated and non-irradiated skin. 
These samples were analysed for photodamage markers (p53, c-Jun, apoptosis), 
inflammatory markers (T-lymfocytes, monocytes, polymorphonuclear leukocytes, 
Langerhans cells) and markers for the oxidative response (lipid peroxidation, 
catalase).
Results Both UVA and UVB induce markers for photodamage and inflammation. 
Although generally comparable effects were seen, UVB showed an earlier and 
more pronounced induction of photodamage markers and an earlier influx of an 
inflammatory infiltrate. Remarkably, lipid peroxidation increased by 882% one hour 
after UVA irradiated compared to an 111% increase in UVB irradiated skin. Catalase 
activity, as a maker for the oxidative defence, decreased by 83% after UVA exposure 
without returning to baseline levels within the studied period.
Conclusions Although maximal infiltrate accumulations were comparable, UVB 
showed earlier induction of markers for inflammation, suggesting that UVB and 
UVA challenges were equivalent in the present experimental approach with respect 
to inflammation. A more pronounced induction of markers for photodamage was 
seen following UVB as compared to UVA. In contrast, markers for oxidative damage 
were expressed substantially more following UVA exposure as compared to UVB 
exposure. It is hypothesised that the early induction of oxidative damage following 
UVA postpones photodamage and inflammation as compared to the dynamics of 
UVB.
2.1.2 Introduction
Exposure to ultraviolet radiation can have deleterious effects, like sunburn, 
photoageing and skin cancer. Understanding the underlying mechanisms is important
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when studying photobiological profiles of different UV spectra. Photobiological 
processes are mediated by type I and type II photochemical reactions. Type I 
reactions are induced directly by UV irradiation, whereas type II reactions are 
indirect and mediated by reactive oxygen species and other oxidative products ( 1 ). 
UVB is considered to induce mainly type I reactions, while UVA is responsible for 
type II reactions. The present study compares UVA and UVB photoresponses and 
focuses on time course relationships between oxidative processes, photodamage and 
UV induced immunomodulation.
Acute excessive UV exposure may result in damage of cellular structures. This 
damage activates protective mechanisms such as the upregulation of the tumour 
suppressor gene p53, which allows the cell to repair the damage or if the damage 
is too extensive to undergo apoptosis. P53 expression is induced 3 hours after UVA 
and UVB irradiation, reaches its maximum at 12 hours and disappears 72 hours after 
exposure. P53 is expressed in all cell layers of the epidermis after UVB exposure, 
whereas after UVA challenge the expression is limited to the basal layers (2-4). 
Apoptotic keratinocytes have the histological appearance of sunburn cells. They 
appear 6  hours after irradiation, peak at 24 hours, and are mainly seen after shortwave 
UV irradiation (UVC and UVB). Sunburn cells appear only sporadically in UVA 
irradiated skin (3,5,6). C-Jun is a marker for the early induction of photoageing and 
is called an early response gene. It is induced 15 minutes post irradiation and peaks 
at approximately 8  hours after UVB irradiation. C-Jun expression after UVA follows 
a similar pattern but is less pronounced (7).
The inflammatory responses following exposure to UVA and UVB are characterised 
by an influx of polymorphonuclear leukocytes up to 14 hours after the irradiation. 
This is followed by an influx of T-lymphocytes, which concentrate perivascularly. 
Futhermore epidermal Langerhans cell counts reduce within one hour after irradiation, 
with complete depletion 24 hours after UVB exposure (8-10). A single dose of 100 
J/cm2 UVA may also reduce the amount of Langerhans cells up to 75% after 24 hours
(11). A comparative study on the above-mentioned photoresponses between UVA and 
UVB is not yet available.
Oxidative processes play a major role in UVA induced photobiological processes, 
which eventually result in photodamage and photoageing. Several authors have 
shown that UVA and UVB induce the formation of reactive oxygen species (12,13). 
Recently, Sander et al. demonstrated in vivo a dose dependent protein oxidation and 
antioxidant depletion by UV radiation. These observations are compatible with the 
demonstration of oxidative products and depleted antioxidant systems in photoaged 
skin (14). These observations suggest that photoageing is associated with protein 
oxidation and antioxidant enzyme depletion. Recently, it was shown that catalase, 
belonging to the anti-oxidant system, is induced selectively by UVA, whilst UVB 
does not induce any catalase activity (15). This observation suggests that there may be 
substantial differences between UVA and UVB with respect to oxidative responses.
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To study processes in vivo, usually biopsies for cellular and molecular studies are 
taken. Recently, Maes et al. described several non-invasive techniques to measure 
oxidation products in the upper cell layers from the skin, such as squalene and 
squalene hydroperoxide (16). Giacomoni et al. described a new technique to study 
catalase, an antioxidant defence, at the skin surface by analysing catalase activity on 
corneocytes removed by adhesive tape (17,18). These two non-invasive techniques 
permit a simplified reproducible analysis of the oxidative defence mechanisms in 
the skin; however so far these parameters have not been studied simultaneously with 
parameters for photodamage and inflammation.
In the present study we combined immunohistochemistry and the two above described 
non-invasive techniques to investigate the time course of photodamage, inflammation 
and oxidative damage of UVA and UVB irradiation. Furthermore, this study compares 
the photobiological responses between UVA and UVB in one experimental study. 
The Minimal Erythema Dose (MED) of UVB and a dose of 60 J/cm2 UVA were 
chosen as the irradiation dose. Several studies use MED for UVA, however in our 
experience no erythema is induced with proper UVB/C shielding when using UVA 
lamps. The other studies indicate that the mean "UVA MED" approaches the dose 
of 60 J/cm2 used in the present study (19-21). Preliminary experiments revealed that 
irradiation with a dose of up to 60 J/cm2 is possible without inducing a more than mild 
transient erythema, directly following exposure.
2.1.3 Material and Methods 
Patients and UV irradiations
Fourteen healthy volunteers with Fitzpatrick Skintype II/III without a history of recent 
excessive sun exposure or tanning were included after written informed consent was 
obtained. The volunteers were divided at random in 2 groups of 7 subjects, an UVA 
and an UVB irradiated group. UVB irradiation was performed in a Waldmann 7001 
cabin equipped with Phillips UV21 broadband UVB lamps. Minimal erythema dose 
testing was performed in each 'UVB irradiation' volunteer and was defined as the 
dose which can induce a just perceptible erythema 24 hours after irradiation with 
broad band UVB. UVA irradiation was performed with a 2100 W Dermalight 2020 
sol 5 (Dr. K. Hönle Medizin technik, München, Germany) equipped with an infrared 
and UVB filter (Coimex Trading BV, Hattem, the Netherlands). The volunteers were 
irradiated at an area of 1 0  x 2 0  cm on the left side of the lower back/buttock with one 
MED broad band UVB or with 60 J/cm2 UVA depending on their randomisation. The 
right side of the lower back/buttocks was designated as control side.
In UVB irradiated volunteers and UVA irradiated volunteers tapestrips, extractions 
and biopsies were collected 1, 4 and 24 hours and 1, 4, 7, 24 and 48 hours after 
irradiation respectively. The biopsies were embedded in Tissue Tek OCT compound
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(Miles Scientific, Naperville, USA), snap frozen in liquid nitrogen and stored at -80 
°C until further analysis. Sections of 6  were cut, air dried and fixed in acetone and 
again stored at -80 °C.
Monoclonal antibodies
The following monoclonal antibodies were used for immunohistochemical analysis 
of photodamage: Monoclonal Murine anti-human (wild type and mutant) p53 protein 
(1:200) (Dakopatts, Glostrup, Denmark) and PhosphoPlus c-Jun (Ser63) II Antibody 
kit (1:50) (New England Biolabs Inc., Beverly, MA, USA) phosphorylation on point 
63 of c-Jun. HE stainings were performed to evaluate epidermal UV induced damage 
and inflammation. Analysis of inflammatory infiltrate was done by assessment 
of T-lymphocytes, Langerhans cells, polymorphonuclear leukocytes (PMN) and 
monocytes/macrophages respectively using the monoclonal antibodies DAKO T-
11 (1:100) (Dakopatts, Copenhagen, Denmark), DAKO T6  (1:100) (Dakopatts, 
Copenhagen, Denmark), DAKO anti-elastase (1:100) (Dakopatts, Copenhagen, 
Denmark), WT14 (1:100) (UMC St Radboud, Nijmegen, the Netherlands).
The non-invasive techniques to study oxidation did not use antibodies but measure 
enzyme activity.
Immunohistochemical staining
The slides were air dried and immersed in a phosphate buffered saline (PBS). 
All slides were incubated for 15 minutes with 20% normal horse serum (Vector 
Laboratories, Burlingame, USA) in 1% bovine serum albumin (BSA, Organon 
Technika, Boxtel, the Netherlands) in PBS and then by 1 hour incubation with the 
primary antibody (p53, c-jun, T11, WT14 and anti-elastase). The slides were washed 
in PBS and incubated with rabbit anti-mouse biotinylated IgG (ABC kit-mouse, 
Vector Laboratories, Burlingame, USA) for 30 minutes. The sections were washed 
again in PBS and incubated with anti-rabbit biotinylated IgG for 30 minutes.
All slides were washed in PBS and incubated with avidin biotin complex solution 
(ABC kit-mouse, Vector Laboratories, Burlingame, USA) for 30 minutes and labelled 
with metal enhanced DAB substrate (Pierce, Rockford, USA) for visualisation.
The slides were counter-stained with Mayer's haematoxylin (Sigma, St. Louis MO, 
USA) and after dehydration with 100% ethanol and histosafe mounted in Permount 
(Fisher Scientific, New Jersey, USA).
For T- 6  an indirect peroxidase technique was used. The slides were washed in 
phosphate-buffered saline and incubated for 1 hour at room temperature with the 
primary antibody. The slides were washed twice in PBS and incubated for 30 minutes 
with rabbit-anti-mouse-immunoglobulins (Dakopatts, Copenhagen, Denmark) 
conjugated with peroxidase, diluted 1:50 in PBS and containing 5% human AB
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serum. After two further washes in PBS and preincubation with sodium acetate buffer 
(pH 4.9) the slides were stained with 3-amino-9-ethyl-carbazole for 10 minutes. The 
slides were counter-stained with Mayer's haematoxylin and mounted in glycerol 
gelatin (Sigma).
Histological examination
The histological examination was performed blindly by two observers. Photodamage 
was measured by counting the number of p53 positive nuclei per mm length of 
section. The epidermal expression of Langerhans cells, c-Jun expression, apoptosis 
and dermal inflammation were scored on a semi-quantitative scale (0 : none present, 
1: minimal, 2: moderate and 3: pronounced amount/staining). T-cells, monocytes/ 
macrophages and polymorphonuclear leukocytes were assessed by scoring the 
percentage of these inflammatory cells in the dermal infiltrate on a semi-quantitative 
scale (0: 0%, 1: 1-4%, 2: 5-24%, 3: 25-49%, 4: 50-74%, 5: 75-100%).
Measurement of lipid peroxides at the skin surface
For the evaluation of skin surface lipid peroxides ethanol washes were collected 
from irradiated and non-irradiated sites on the lower back and stored at -80°C until 
further analysis. Using a HPLC technique as described by Maes et al. squalene and 
squalene hydroperoxide levels were measured (16). Briefly: squalene and squalene 
hydroperoxide were separated from other lipids on a reversed phase C18 column. 
Squalene was detected at 220 nm, while squalene hydroperoxide was detected after 
post-column reaction with iron (II) and sulfosalicylic acid. The lipid peroxide value 
was defined as mol% squalene hydroperoxide over residual squalene.
Measurement of catalase activity on tape strippings from stratum corneum
For the evaluation of antioxidant enzyme activity in the stratum corneum twenty 
successive D-squame® tape strippings (CuDerm Corporation, Dallas, TX, USA) were 
collected from the lower back in the UVA irradiated subjects and stored at -80°C until 
further analysis. Enzyme activity was evaluated as described before (15,22). Briefly: 
the assesment of catalase activity is based on the ability to reduce hydrogen peroxide 
using methanol as proton donor, leading to the formation of formaldehyde, which can 
be detected after reaction with Purpald (Sigma-Aldrich Corporation, St.Louis, MO, 
USA). Specific catalase activity was obtained after normalisation to the total protein 
content on the same tape stripping, which was quantified as the total amount of amino 
acids after acid hydrolysis at high temperature.
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Statistical evaluation
The data have been analysed using the Statistica Statistical '98 package 5.1. Data 
are expressed as means ± SEM. For statistical analysis of the immunohistochemical 
part one-way ANOVAs were performed to asses significant changes in expression 
during the time after irradiation. If the expression changes significantly after 
irradiation Duncan's post hoc comparisons test was performed to establish at which 
timepoints significance was reached. For the non-invasive techniques a Student t-test 
(paired observations, two tailed distribution, two sample unequal variance). Possible 
correlations were analysed with the Pearson product-moment correlation. A p-value
< 0.05 was considered significant.
2.1.4 Results
Both UVA and UVB irradiation were well tolerated by the volunteers. 60 J/cm2 
UVA only resulted in a transient slight heat erythema and some immediate pigment 
darkening.
Figure 2-1-1 Time course of p53 expression after UVA and UVB exposure. UVB induces an 
earlier and more pronounced expression of p53.
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Figure 2-1-2 Time course of inflammatory response after UVA and UVB exposure. The UVB 
induced inflammatory response reaches significance at 4 hours post irradiation whereas UVA 
reaches significance 7 hours post irradiation.
Photodamage
P53 expression showed a significant increase in both UVA and UVB irradiated 
individuals (p<0.01). Seven hours after UVA exposure significance was reached 
(p<0.01). In UVB exposed skin significance was reached 4 hours after exposure 
(p<0 .0 1 ), which peaked 2 0  hours later (p<0 .0 1 ), without returning to baseline levels 
within the studied time frame (Figure 2-1-1).
Phosphorylated c-Jun also showed a significant increase in expression (p<0.01) 
starting 24 hours after irradiation for UVA (p<0.01) and 4 hours after irradiation with 
UVB (p<0.01), which also did not return to normal levels within the study period. 
UVA as well as UVB irradiation did not induce keratinocyte apoptosis at the used 
dosages, as no sunburn cells were seen at any of the time points.
Inflammation
Both UVB and UVA induced dermal perivascular inflammation (p<0.01), which was 
more pronounced and earlier in UVB irradiated skin. UVA induced inflammation 
reached significance 7 hours post irradiation and peaked at 48 hours (p<0.01),
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Figure 2-1-3 Time course of lipid peroxidation levels in UVA and UVB irradiated skin. An up 
to 882% increase in lipid peroxidation is seen 1 hour after UVA irradiation compared to only
111% in UVB irradiated skin.
whereas UVB induced inflammation reached significance 4 hours after irradiation and 
increased at least up to 24 hours after irradiation (p<0.01) (Figure 2-1-2). The increase 
in perivascular infiltrate was mainly attributed to the influx of T-lymphocytes in both 
UVB (p<0.01) and UVA (p<0.01) irradiated skin. The perivascular infiltrate did not 
return to baseline levels. We did not detect any change in the number of Langerhans 
cells, polymorphonuclear leukocytes and monocytes/macrophages count.
Oxidative processes
Lipid peroxidation was evaluated as the amount of squalene hydroperoxide (SO) on 
the skin surface as detected by HPLC. UVA induced a 882% increase in SO levels 
within 1 hour after irradiation (p<0.01), after which the SO levels gradually returned 
to baseline levels at 24 hours. During this decrease, no significant difference with the 
control was seen (Figure 2-1-3).
In contrast, UVB irradiation only resulted in a 111% increase in SO levels (p<0.01), 
which returned to baseline levels within 4 hours after irradiation (Figure 2-1-3). 
Catalase activity, as a marker for antioxidant defence, decreased by 69% 1 hour after 
and 83% 3 hours after UVA irradiation. We did not observe normalisation 48 hours 
after UVA irradiation (Figure 2-1-4).
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Figure 2-1-4 Time course of catalase activity in UVA irradiated and non-irradiated skin. A 
significant decrease in catalase activity in UVA irradiates skin is observed, which did not return 
to baseline levels within the studied timeframe.
Correlations
There were no statistically significant correlations between lipid peroxidation or 
catalase activity and the markers for photodamage and inflammation.
2.1.5 Discussion
The present study reconfirms that UVB as well as UVA induce expression of p53 
and phosphorylated c-Jun (3,4,7). For UVB, the expression was more pronounced 
than for UVA. Furthermore, UVA induced p53 expression declined 24 hours after 
irradiation, while UVB induced p53 seemed to increase further. Phosphorylated c- 
Jun (early response gene) showed an earlier expression after UVA as well as UVB 
irradiation. At the used irradiation dosages of 1 MED UVB and 60 J/cm2 UVA no 
sunburn cells were detected. This finding is in concordance with studies by Gilchrest 
et al. (2 0 ), although other investigations have described the appearance of sunburn 
cells at erythematogenic UVA doses (3,5,6).
Perivascular and upper dermal infiltrate with predominantly polymorphonuclear 
leukocytes and T-lymphocytes was also observed. No significant change in 
polymorphonuclear leukocytes and monocytes/macrophages ratio in the perivascular
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inflammation was seen. No depletion of Langerhans cells was noted. This could 
probably be attributed to the low and single challenge dosage of UVA and UVB. It 
has been reported before that repeated low dose (1.5 MED) UVB and (0.5 MED) 
UVA can reduce the epidermal Langerhans cell count by at least 50% (8,19).
Lipid peroxidation as measured by the squalene peroxide levels was more pronounced 
in UVA irradiated skin (up to 882% increase) compared to UVB irradiated skin 1 
hour after irradiation. Four hours after irradiation the mean peroxide levels of the 
irradiated side were still increased compared the non-irradiated control side, although 
the values were not significantly different. Within the following hours, the squalene 
peroxide levels returned to similar levels as the controls. Catalase (an important 
oxygen radical scavenger) activity in the upper epidermis, decreased with 69% within 
1 hour after UVA irradiation and did not return to normal levels within 48 hours. This 
is in concurrence with our previous report, where we have shown that recovery of 
catalase activity occurs in 3-4 weeks after UVA exposure at an age-dependent rate 
(15). Interestingly, UVB exposure did not affect catalase activity (15). Recently, 
Sander et al. demonstrated for the first time that photoaging is indeed associated 
with protein oxidation (14). Furthermore, reactive oxygen species can result in 
DNA damage (23). It could thus be hypothesised that the UVA and UVB induced 
production of reactive oxygen species may influence photoageing (e.g. c-Jun) and 
photodamage (p53, apoptosis).
There was an intriguing delay in expression of the p53 and c-Jun markers after UVA 
irradiation. It could be hypothesised that this delay can be attributed to the preference 
of UVA for type II (oxidative pathway) photochemical reactions. It has been shown 
that oxidative stress can damage keratinocytes and induce expression of p53 and c- 
Jun (24,25). Furthermore, type II (indirect) reactions take more time to damage cells 
than the direct type I reactions. The present study shows that oxidative processes 
are more involved in UVA induced photobiological processes. These processes may 
account for the delay in c-Jun and p53 expression.
This study shows that no statistically significant correlation exists between any of the 
oxidative damage markers and photoaging, photodamage and inflammation markers, 
as calculated by Pearson product-moment correlations.
In the present study parameters for photodamage, inflammation and oxidative 
changes, following UVB and UVA challenge, have been studied in one single 
experimental approach. The MED for UVB can be determined easily. However, the 
MED for UVA is difficult to assess as relatively high doses are required, which imply 
that slight UVB contamination in these UVA sources confuse the MED substantially. 
Therefore it is virtually impossible to generate equivalent doses of UVB and UVA 
with respect to erythema. In the present study we approached the UVA dose range, 
which has been suggested to be the MED. This range has been reported to be 14-56 
J/cm2 (19-21).
Assuming that the present study has approached equivalent challenges of UVB and
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UVA, several remarkable differences between UVA and UVB were observed. Firstly 
a highly significant and substantial difference was observed between UVA and UVB 
with respect to the induction of lipid peroxidation (fig. 2-1-3). Another difference was 
the relatively early induction of p53 and c-Jun following UVB exposure as compared 
to UVA exposure.
In conclusion, UVB showed an earlier and pronounced induction of markers for 
photodamage compared to UVA in this in vivo model. Therefore, induction of 
photodamage is not restricted to UVB but also is a hazard of UVA. Furthermore, 
inflammation was also earlier induced in UVB irradiated skin. Remarkably, lipid 
peroxidation proved to be a highly characteristic early phenomenon of UVA induced 
damage, which was far less expressed following UVB. Therefore, skinageing is a 
serious hazard of UVA exposure.
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2.2 The differential effect of broad band versus narrow band UVB 
with respect to photodamage and cutaneous inflammation
2.2.1 Abstract
Background Since Fischer reported on the superiority of 313 nm UVB compared to 
broad band UVB in the treatment of psoriasis, narrow band UVB has become the 
main phototherapeutical modality in several countries. There is some discussion 
about the safety and photobiological effects of narrow band UVB. In the present 
study narrow- and broad band UVB have been compared with respect to parameters 
for photodamage and inflammation.
Patients/methods Fourteen healthy volunteers were randomized in two groups. 
Both groups were irradiated with 3 Minimal Erythema Doses (MED) of narrow 
or broad band UVB respectively. Before and 4, 24 and 48 hours after irradiation 6  
mm biopsies were taken for immunohistochemical analysis of p53, apoptosis and 
p16 (photodamage parameters) and T-cells, polymorphonuclear leukocytes and 
Langerhans cells (inflammatory cells).
Results Mean MED for narrow band UVB was 8.125 times higher than broad band 
UVB. Significant changes in expression were seen for all parameters except for 
p16. P53, apoptosis, T-cells and polymorphonuclear leukocytes increased, while 
Langerhans cell count decreased significantly. No significant differences were seen 
between the narrow and broad band UVB.
Conclusions In conclusion: following irradiation of 3 MED narrow band UVB 
and broad band UVB safety parameters for carcinogenesis and inflammation were 
induced to the same extent. As narrow band UVB is more effective than broad band 
UVB, the present study suggests superiority of narrow band UVB as a treatment with 
a better benefit risk ratio.
2.2.2 Introduction
Broad band UVB (290-320 nm) and Psoralen UVA photochemotherapy have been the 
main phototherapeutic treatments for several chronic inflammatory skin diseases for 
many decades. In 1976 Fischer demonstrated that narrow band (313 nm) UVB was 
more effective in the treatment of psoriasis than broad band UVB (1). This finding 
was confirmed by Parrish & Jaenicke (2). Inspired by these results a new fluorescent 
bulb, the TL-01 lamp, was developed by Philips which emits almost exclusively 
311/312 nm UVB. Narrow band UVB is not only more effective than broad band 
UVB, but it also approaches the efficacy of PUVA photochemotherapy with less side 
effects (3,4). At present, narrow band UVB is replacing broad band UVB and even 
PUVA in several countries as the main modality in phototherapy for most chronic
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inflammatory skin diseases.
As narrow band UVB excludes the short wavelengths of the UVB spectrum, and 
is closer to UVA, higher doses are needed to induce a photobiological effect (5). 
Therefore, in the treatment of psoriasis, where near-erythematogenic doses are 
recommended, individual exposures are at a higher dose, while the duration of a 
treatment course is shorter with less exposures (6,7). Cumulative dosages for narrow 
band UVB are generally higher compared to doses with broad band UVB (7,8).
A major question remains to be answered: To what extent is narrow band UVB different 
from broad band UVB with respect to photodamage, ageing and inflammation?
The aim of the present study was to investigate whether these two UVB modalities 
induce different photobiological effects to markers for photocarcinogenesis and 
inflammation.
Markers for photocarcinogenesis are p53, p16 and apoptosis. Several reports have 
indicated that narrow band UVB may be more photocarcinogenic than broad band 
UVB (9-11), while others contradict these (12). Single exposure to high dose broad 
and narrow band UVB has been shown to cause a substantial induction of p53, a tumor 
suppressor gene, and apoptosis (histologically seen as sunburn cells) (13,14). P16 is a 
nucleotide excision repair protein, which is most strongly expressed in melanocytes 
after shortwave UV irradiation (15,16). It is unknown if there are any differences in 
expression of these markers between broad and narrow band UVB.
Markers for inflammation are T6 , T11 and elastase. UVR exposure results in an 
inflammatory reaction with at first a predominantly neutrophil perivascular infiltrate. 
Subsequently Langerhans cells migrate from the epidermis into the dermis (14,17,18). 
There are no data available on differences in expression between broad and narrow 
band UVB with respect to this matter.
In this present study doses of 3 MED of narrow band UVB and broad band UVB were 
given to healthy volunteers. At 4, 24 and 48 hours after exposure punch biopsies were 
taken and immunohistological assessment was performed on the following markers: 
p53, p16, apoptosis, T6 , T11, elastase.
2.2.3 Material and Methods 
Patients and UVB irradiation
Fourteen healthy volunteers with Fitzpatrick's skin type II and III were included after 
their written informed consent was obtained. The volunteers were randomised in a 
broad band UVB and a narrow band UVB group. The irradiation was performed in 
a Waldmann UV 7001 K phototherapy cabin equipped with broad band UVB lamps 
or narrow band UVB lamps. Minimal erythema doses (MED) were assessed and 
the volunteers were irradiated with 3 MED broad or narrow band UVB, depending 
on their randomisation. At 4, 24 and 48 hours after irradiation punch biopsies were
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obtained from unirradiated skin and the irradiated areas on the buttocks under local 
anaesthesia with 1% Xylocain and Adrenalin. Biopsies were embedded in paraffin 
after a 4-hour fixation in formaldehyde. The study was approved by the ethical 
committee of the University Medical Centre Nijmegen, the Netherlands.
Minimal erythema dose assessment
MED was defined as the UVB dose required to achieve a just perceptible erythema 24 
hours after irradiation. Six circular areas of 2.5 cm in diameter located horizontally 
just above the buttocks were irradiated with increasing doses of broadband UVB. For 
patients with skin type II, the following broad band UVB range was used: 0.05-0.09­
0.12-0.16-0.20-0.27 J/cm2 and for skin type III: 0.05-0.10-0.15-0.20-0.30-0.40 J/cm2. 
Narrow band UVB ranges were identical for skintype II and III: 0.50-0.70-0.90-1.10­
1.30-1.50 J/cm2.
Monoclonal Antibodies
The following monoclonal antibodies were used to evaluate photodamage: Monoclonal 
Murine anti-human (wild type and mutant) p53 protein (1:200) (Dakopatts, Glostrup, 
Denmark) and Ab-4 Mouse anti-human p16 (1:100) (Neomarkers, Fremont, 
USA). HE stainings were performed to evaluate epidermal UV induced damage 
and inflammation. Analysis of inflammatory infiltrate was done by assessment 
of T-lymphocytes, Langerhans cells and polymorphonuclear leukocytes (PMN) 
respectively using the monoclonal antibodies DAKO T-11 (1:100) (Dakopatts, 
Copenhagen, Denmark), DAKO T6  (1:100) (Dakopatts, Copenhagen, Denmark) and 
DAKO anti-elastase (1:100) (Dakopatts, Copenhagen, Denmark).
Immunohistochemical Staining
Six-micrometer paraffin sections were dewaxed with histosafe (Adamas, Amerongen, 
the Netherlands), and dipped in a series of graded ethanol from 100% to 50% and 
rehydrated in demineralized water. For p53 and p16 the slides were pretreated in a 
10 mM citrate buffer (high temperature microwave retrieval technique by Cattoretti) 
at 450 W in a microwave oven for approximately 9 minutes and left to cool for 45 
minutes. The slides were then air dried and immersed in a phosphate buffered saline 
(PBS).
All slides were incubated for 15 minutes with 20% normal horse serum (Vector 
Laboratories, Burlingame, USA) in 1% bovine serum albumin (BSA, Organon 
Technika, Boxtel, the Netherlands) in PBS and then by 1 hour incubation with the 
primary antibody (p53, p16, T11 and anti-elastase). The slides were washed in PBS 
and incubated with rabbit anti-mouse biotinylated IgG (ABC kit-mouse, Vector
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Figure 2-2-1 Mean p53 expression (+/- SD) for broad and narrow band UVB increases 
significantly up to 24 hours post irradiation. No significant difference between both groups is
seen.
Laboratories, Burlingame, USA) for 30 minutes. The sections were washed again in 
PBS and incubated with anti-rabbit biotinylated IgG for 30 minutes.
All slides were washed in PBS and incubated with avidin biotin complex solution 
(ABC kit-mouse, Vector Laboratories, Burlingame, USA) for 30 minutes and labelled 
with metal enhanced DAB substrate (Pierce, Rockford, USA) for visualisation.
The slides were counter-stained with Mayer's haematoxylin (Sigma, St. Louis MO, 
USA) and after dehydration with 100% ethanol and histosafe mounted in Permount 
(Fisher Scientific, New Jersey, USA).
For T- 6  an indirect peroxidase technique was used. After dewaxing, the slides were 
washed in phosphate-buffered saline and incubated for 1 hour at room temperature 
with the primary antibody. The slides were washed twice in PBS and incubated 
for 30 minutes with rabbit-anti-mouse-immunoglobulins (Dakopatts, Copenhagen, 
Denmark) conjugated with peroxidase, diluted 1:50 in PBS and containing 5% 
human AB serum. After two further washes in PBS and preincubation with sodium 
acetate buffer (pH 4.9) the slides were stained with 3-amino-9-ethyl-carbazole for 10 
minutes. The slides were counter-stained with Mayer's haematoxylin and mounted in 
glycerol gelatin (Sigma).
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Sunburn cells
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Figure 2-2-2 Mean sunburn cell count (+/- SD) for broad and narrow band UVB increases 
significantly up to 48 hours post irradiation. No significant difference between both groups is
seen.
Histological examination
The histological examination was performed blindly by two observers. Photodamage 
was measured by counting the number of p53 positive nuclei per mm length of section. 
The epidermal expression of p16, Langerhans cells and apoptosis as well as dermal 
inflammation were scored on a semi-quantitative scale (0 : none present, 1 : minimal, 
2: moderate and 3: pronounced amount/staining). T-cells and polymorphonuclear 
leukocytes were assessed by scoring the percentage of these inflammatory cells in the 
dermal infiltrate on a semi-quantitative scale.
Statistical evaluation
The data have been analysed using the Statistica Statistical package. Data are 
expressed as means ± SEM. For statistical analysis two way ANOVAs were 
performed, if applicable followed by Duncan's post hoc comparisons test. A p-value
< 0.05 was considered significant.
2.2.4 Results
UV exposure was well tolerated by the volunteers, although a pronounced erythema
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Figure 2-2-3 Mean T-cell score (+/- SD) for broad and narrow band UVB increases significantly 
24 hours post irradiation. No significant difference between both groups is seen.
was visible on the irradiated areas. No visible change in pigmentation was observed. 
Mean MED for broad band UVB was significantly lower than for narrow band UVB 
(p=0.0000). The difference between the mean doses of broad band and narrow band 
UVB to induce a just perceptible erythema was 1.14 J/cm2. Narrow band UVB MED 
doses were 8.125 times higher than broad band UVB MED doses.
Broad band and narrow band UVB at equivalent MED doses were equally potent 
in inducing p53 (p=0.8815), apoptosis (p=0.9131) and p16 expression (p=0.9835). 
The number of sunburn cells continued to increase significantly up to 48 hours 
after irradiation (p=0.0000). In contrast, p53 expression reached a maximum at 24 
hours post irradiation, followed by a decline (p=0 .0 0 0 0 ) (see figure 2 -2 - 1  and 2 -2 ­
2). P16 expression did not show any significant change following UVB exposure 
(p=0.5212).
Both broad and narrow band UVB showed a moderate but significant increase 
in perivascular dermal infiltrate up to 48 hours after irradiation (p=0.0000), 
predominantly consisting of T-cells (p=0.0000) and polymorphonuclear leukocytes 
(p=0.0000). In contrast, a significant decrease in epidermal Langerhans cell count was 
observed from 4 hours up to 48 hours post broad and narrow band UVB exposure.
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Figure 2-2-4 Mean PMN score (+/- SD) for broad and narrow band UVB increases significantly 
24 hours post irradiation. No significant difference between both groups is seen.
No significant differences in accumulation of T-cells and PMNs or decrease of 
Langerhans cells between broad and narrow band UVB were observed (p>0.2947) 
(see figure 2-2-3 to 2-2-5).
2.2.5 Discussion
The present study shows that mean MED doses were 8.125 times higher for narrow 
band UVB compared with broad band UVB. Several other studies have also shown 
that MED doses were significantly higher for narrow band UVB ranging from 2.8­
4.52 times higher in healthy volunteers and up to 10.8 times higher in hairless mice 
(5,11,19).
In treating several chronic inflammatory diseases such as psoriasis narrow band UVB 
is regarded as more effective compared to broad band UVB and as equally effective 
with less side effects as compared to PUVA (3,7).
Previous studies in mice however have shown that narrow band UVB may be more 
carcinogenic than broad band UVB (9-11). The median tumor induction time of 
repeated near erythematous doses of narrow band UVB in albino Skh-1 hairless 
mouse (hr/hr) was 14 weeks compared to 21 weeks with broad band UVB irradiation. 
The present study did not show any differences in p53, p16 and apoptosis in vivo
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Figure 2-2-5 Mean Langerhans cell count (+/- SD) for broad and narrow band UVB decreases 
significantly from 4 hours and onwards post irradiation. No significant difference between both
groups is seen.
in healthy human volunteers and therefore seems to confirm previous experimental 
mouse studies that did not show enhanced narrow band UVB photocarcinogenesis 
( 1 2 ,2 0 ).
With respect to inflammation the present study confirms that a single high dose 
challenge of both broad and narrow band UVB induces a moderate perivascular 
influx of inflammatory cells, predominantly T-lymphocytes and polymorphonuclear 
leukocytes, with a pronounced reduction of epidermal Langerhans cells (21).
The present study demonstrates that after irradiation with 3 MED narrow band and 
broad band UVB similar effects on inflammation and photodamage are induced. The 
higher efficacy of narrow band UVB in the treatment of several skin diseases compared 
with broad band UVB and PUVA results in a reduced number of irradiations needed 
to induce a remission (6 ). The present study indicates that irradiation with narrow 
band and broad band UVB at 3 times the MED has a similar safety profile. Therefore, 
it can be concluded that narrow band UVB has an improved benefit ratio as compared 
to broad band UVB.
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2.3 High dose long wave visible light induces perinuclear 
vacuolization in vivo but does not result in early photoageing and 
apoptosis
2.3.1 Abstract
With the advancing widespread use of photodynamic therapy, questions arise about 
the necessity to protect the adjacent healthy skin from high dose long-wave light. 
The aim of the present study is to investigate the effects of high dose visible light on 
the skin of healthy volunteers with focus on apoptosis, DNA damage, inflammation, 
melanogenesis and induction of matrix metalloproteinases (MMP). Fourteen healthy 
volunteers were included and irradiated daily on their buttocks with 1300 kJ/m2 
long wave visible light (560-780 nm) on 5 consecutive days with a cumulative dose 
of 6500 kJ/m2. In each volunteer six biopsies were taken before and 24 hours after 
irradiation on day 1, 2, 3 and 5 and on day 8  and 12. Frozen and paraffin sections 
were investigated by measuring parameters for photodamage (apoptosis, p53, 
phosphorylated c-Jun), and skin ageing (phosphorylated c-Jun, MMP-1, elastin 
content) and melanogenesis (melan-A). Although no sunburn cells were seen, a 
significant increase in perinuclear vacuolization was noted (p<0.0003) from day 5 
till 7 days after the last irradiation. There was no expression of phosphorylated c-Jun, 
whereas the expression of p53, Melan A, MMP-1 and elastin content did not change. 
High dose visible light induces a significant increase in perinuclear vacuolization, but 
does not result in apoptosis, photodamage or early induction of skin ageing.
2.3.2 Introduction
Studies in photodermatology have been focused mainly on the ultraviolet light (UV) 
part of the electromagnetic radiation spectrum. It is known that UV light contains 
sufficient energy to result in readily discernible biological effects in the skin. Visible 
light has up till recently been regarded to be without any significant photobiological 
effect on the skin. With the recent developments in photodynamic therapy, visible 
light has become increasingly interesting for researchers, especially in combination 
with appropriate photosensitizers, such as 5-amino-levulinic acid. The spectrum 
of the visible light used in dermatological PDT ranges from 560 till 780 nm. With 
the emerging widespread use of photodynamic therapy the safety question for 
surrounding normal healthy skin and personnel arises. As visible light has always 
been regarded as harmless for healthy skin, almost no research has been done whether 
this supposition is correct.
Most visible light research has focused on the near UV spectrum ranging from 400­
450 nm. As most effects in photobiology are not induced by one specific wavelength
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but by a whole range of wavelengths it is attractive to hypothesize that near UV 
irradiation might have similar but perhaps less potent effects than UVA irradiation. 
Several studies have shown that near UV irradiation results in UVA-like effects, 
mainly consisting of type II reactions such as DNA strand breaks due to singlet 
oxygen species generation mediated by endogenous photosensitizers like billirubin 
(1,2). But what about the effect of electromagnetic radiation in the red-light spectrum 
as used in PDT? Again it is attractive to speculate that similar effects can be seen in 
the red-light spectrum. 5-Amino levulinic acid, as used in PDT, is an endogenous 
substance and a precursor of the endogenous photosensitizer protoporphyrin IX. 
Protoporphyrin IX produces singlet oxygen species after irradiation with light in the 
Soret band range. Therefore it is possible that red light may result in singlet oxygen 
mediated damage. Studies on the photobiological effects of visible light are sparse. 
Edström et al. have shown that high dose visible light (400-800 nm) can result in 
an increased p53 expression in vivo. The doses used are rather low and given over 
4 weeks. The number of volunteers was small with only 3-4 biopsies per time point 
(3-5).
UVA irradiations may induce photoageing. Indeed with prolonged UV exposure skin 
wrinkling occurs due to loss of collagen content and elastin fragmentation (6,7). 
Early markers for this process are phosphorylated c-Jun and MMP expression (8 ). 
Photoageing in a later phase is marked by elastosis and elastin fiber fragmentation. 
High dose UVA-1 has remarkable effects on morphea, which may be regarded, at 
least to some extent as a strongly increased photoageing process. It is attractive to 
speculate that high dose visible light may have similar effects, with respect to skin 
ageing.
In the present study the effects of high dose visible light on skin of healthy 
volunteers are investigated with respect to melanogenesis (Melan A), skin ageing 
(phosphorylated c-Jun, MMP-1, elastin content) and photodamage (apoptosis, p53, 
phosphorylated c-Jun). No Minimal Erythema Dose testing was performed as visible 
light, which includes the used wavelength range, is not known to induce erythema, 
furthermore a recent study showed that the physical dose determines the amount of 
photodamage and not the biological dose as defined by MED's (9).
2.3.3 Material & methods
This study was approved by the regional Ethical Committee. Fourteen young healthy 
volunteers (mean age 23.3 range 19-32) with skin type I-III were included in this 
study after giving written consent. To avoid age-related changes in the photobiological 
response of the skin only non-smoking volunteers under the age of 35 years, without 
a history of skin disease or prolonged sun or UV exposure, and without clinical 
visible photodamaged skin were included.
Irradiation was given on 5 consecutive days with a Waldmann 1200 L PDT lamp
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(Herbert Waldmann GmbH & Co., Villingen-Schwenningen, Germany), which uses 
a 1200 watt Philips metal halogen lamp (MSR 1200 HR, Philips B.V., Eindhoven, the 
Netherlands), which has an emission spectrum of 560-780 nm after filtering with the 
build-in dichroic cut-off filters (DT Rot and Calflex-3000, Balzers Optik, Nurnberg, 
Germany). The surrounding skin was protected with light impenetrable cloth. Each 
day 1300 kJ/m2 was given on the sun protected area of the buttocks to a cumulative 
dose of 6500 kJ/m2. Before each irradiation the lamp was allowed to warm up for 10 
minutes. To minimize the number of biopsies the volunteers were randomized in a 
paraffin and cryo embedding group for microscopical analysis. On days 1, 2, 3 and 
5, 3 mm punch biopsies were taken immediately before the irradiation, in addition
3 mm punch biopsies were taken on days 8  and 12, under local anesthesia with 1% 
Xylocain and Adrenalin. Depending on randomization, biopsies were snap frozen 
in Tissue-Tec OCT compound (Miles Scientific, Naperville, USA) or embedded in 
paraffin after a 4-hour fixation in formaldehyde.
Monoclonal antibodies
The following monoclonal antibodies were used on paraffin sections: monoclonal 
murine anti-human (wild type and mutant) p53 protein (1:200) (Dakopatts, Glostrup, 
Denmark), PhosphoPlus c-Jun (Ser63) II (1:50) Antibody kit (New England Biolabs 
Inc., Beverly, MA, USA), which detects phosphorylation on point 63 of c-Jun, 
monoclonal murine anti-elastin antibody (1:500) (Sigma, St Louis, USA) and 
monoclonal murine anti-human Melan A (1:50)(MART-1, Oncogene, San Diego, 
USA). Hematoxylin and eosin (H&E) staining was performed on paraffin embedded 
sections to evaluate epidermal UV induced damage and inflammation. Staining for 
monoclonal murine anti-human MMP-1 (1:15) (Oncogene, San Diego, USA) was 
performed on cryo sections. As controls biopsies 24 hours after irradiation were taken 
from two MED UVB irradiated healthy skin and prolonged (approx. 5000 kJ/m2) 
UVA-1 irradiated skin was used as controls. Keratinocyte apoptosis was evaluated by 
identifying sunburncells in the epidermis.
Immunohistochemical staining
All slides were processed side-by-side. Six |im paraffin sections were dewaxed with 
histosafe (Adamas, Amerongen, the Netherlands), and dipped in a series of graded 
ethanol from 100% to 50% and rehydrated in demineralized water. The slides were 
pre-treated in a 10 mM citrate buffer (high temperature microwave oven retrieval 
technique by Cattoretti (10)) at 450 W in a microwave oven for approximately 9 
minutes and left to cool for 45 minutes. The slides were then air dried and immersed 
in a phosphate buffered saline (PBS). For the elastin staining this step was substituted 
by 5 minute trypsinization with trypsine-CaCl2 solution.
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For p53, elastin and Melan A this initial step was followed by incubation for 15 
minutes with 20% normal horse serum (Vector Laboratories, Burlingame, USA) in 
1% bovine serum albumin (BSA, Organon Technika, Boxtel, the Netherlands) in PBS 
and then by 1 hour incubation with the primary antibody. The slides were washed in 
PBS and incubated with horse anti-mouse biotinylated IgG (ABC kit-mouse, Vector 
Laboratories, Burlingame, USA) for 30 minutes. For phosphorylated c-Jun the initial 
step was followed by incubation for 15 minutes in 20% normal goat serum (Vector 
Laboratories, Burlingame, USA) and by 1 hour incubation with the anti-c-Jun or anti- 
ser73-phosphorylated c-Jun antibody (1:50). The sections were washed again in PBS 
and incubated with anti-rabbit biotinylated IgG for 30 minutes.
All slides were washed in PBS and incubated with avidin biotin complex solution 
(ABC kit-mouse, Vector Laboratories, Burlingame, USA) for 30 minutes and labeled 
with metal enhanced DAB substrate (Pierce, Rockford, USA) for visualization.
All slides were counter-stained with Mayer's haematoxylin (Sigma, St. Louis MO, 
USA) and after dehydration with 100% ethanol and histosafe mounted in Permount 
(Fisher Scientific, New Jersey, USA).
MMP-1 staining was performed on 6  |im cryostat sections fixed in 100% acetone 
following the above-mentioned procedure, starting with the first incubation. After 
counter-staining with Mayer's haematoxylin (Sigma, St. Louis MO, USA) the 
sections were mounted in glycerol-gelatin.
Histological examination and scoring of immunostaining results
The histological examination was performed blindly by two independent observers 
(MT & TS). Photodamage was measured by counting the number of p53 and 
phosphorylated c-Jun positive nuclei as well as the number of sunburn cells and cells 
with perinuclear vacuolization both per 1000 epidermal cells. Sunburn cells were 
defined as epidermal cells with pyknotic nuclei and a strong eosinophilic cytoplasm 
and perinuclear vacuolization as epidermal cells with pyknotic nuclei with large 
cytoplasmatic vacuoles around the nuclei and without the eosinophilic cytoplasm. 
Perinuclear vacuolization was only quantified in paraffin sections. Melanin 
containing cells were scored by counting the amount of Melan A positive cells per 
1000 epidermal cells. Inflammation, elastin content and MMP-1 were described 
qualitatively and semi-quantitatively.
Statistical evaluation
The data have been analyzed using the Statistica 5.5 Statistical package (http:// 
www.statsoft.com/). Data are expressed as means ± SEM. For statistical analysis One­
way Analysis of Variance (ANOVA)-analysis (repeated measures) and a Duncan-test 
were performed. A p-value < 0.05 was considered significant.
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Figure 2-3-1 Perinuclear vacuolization before and 12 days after exposure of high dose long
wave visible light.
2.3.4 Results
Treatment was well tolerated by all volunteers, and all described it as very 
comfortable. Only in one volunteer slight heat-induced erythema was noted once 
immediately post-irradiation.
None of the volunteers experienced other local effects. No visible change 
in pigmentation was seen. In the UVA-1 irradiated control a pronounced 
hyperpigmentation was seen with moderate wrinkling of the skin.
Although H&E staining did not show any sunburn cells, a significant increase was 
observed of epidermal cells with small, but not pyknotic, nuclei and perinuclear 
vacuolization (figure 2-3-1). This increase was significant in a One-way Analysis of 
Variance (p=0.0003). As can be seen in figure 2-3-2 this increase was significant in 
the Duncan test from day 5 onwards compared to the previous time points. On day 12 
we still noted an increase of these cells.
No inflammatory infiltrate was visible.
No significant change in p53 (p=0.1864) expression was seen (figure 2-3-3). 
Phosphorylated c-jun expression was not seen in any of the slides, although our 
positive (2 MED UVB irradiated) control did stain positive. Elastin fibers showed 
clear presence of candelabra-like structures and no signs of elastosis or fragmentation 
of fibers during and after the irradiation period.
Dermal MMP-1 expression was visible in dendritic cells in all the slides, but no 
significant changes were seen as compared to the unirradiated control skin of each 
subject.
No clinical change in pigmentation was seen. This was confirmed by the Melan A 
staining (p=0.1923).
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Figure 2-3-2 Mean perinuclear vacuolization (±SD) increases after exposure to high dose long 
wave visible light while not returning to normal up to 7 days after the last exposure
2.3.5 Discussion
To the best of our knowledge the photobiological effects of visible light on human 
skin have not been studied in depth before. However, several authors have speculated 
that short wave visible light (400-500 nm) can have similar but less pronounced 
photobiological effects on the skin as UVA light. These mainly consist of singlet 
oxygen mediated processes (indirect = type II), and not of direct effects like UVB 
does (direct = type I). This can be explained by the different energy levels of photons 
at different wavelengths as described by the following formula ( 1 1 ).
1.98-10-19 watt seconds 
Ephoton = h v  (with: h = Planck constant) = wavelength in nanometers
This formula implies that UVB with shorter wavelengths has much more energy 
than UVA and even more than visible light. UVB has enough energy to excite DNA 
molecules directly, while UVA can only exert such effect via endogenous photoactive 
substances (porphyrins), which result in singlet oxygen formation, which in turn 
reacts with DNA and other molecules (1,2). Physiologically there is only a limited 
amount of these photoactive substances available in the skin, which implies that after
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Figure 2-3-3 Mean p53 expression (+SD) does not change significantly during repeated high
dose visible light irradiation (p=0.1864)
some time these substances get depleted, resulting in an only limited damage (12,13). 
Studies have shown that near UVA visible light can result in DNA single strand 
breaks (14), p53 induction (3) and immediate pigment darkening (15,16).
As PDT uses the endogenous porphyrin pathway with an excitation spectrum of 
630-635 nm, it may be hypothesized that long wave visible light can excite the small 
amount of endogenous protoporphyrin IX and thus result in singlet oxygen mediated 
effects. Edstrom et al. have studied high dose visible light (3 irradiations per week, 
with a cumulative dose of 15.120 kJ/m2 over 4 week period). They used a filtered 
Xenon lamp with an emission spectrum of 400-800 nm wavelength (4,5). In fact 
their study reconfirms that near UVA light can induce minimal but significant p53, 
Ki67 and p21waf expression (3). A limitation of their study was that each observation 
consisted of only 3 randomly selected volunteers from their pool of 12 subjects.
In contrast to the study of Edstrom et al. we have specifically chosen to exclude the 
near UVA spectrum and to look specifically at the wavelengths used in dermatologic 
photodynamic therapy. Our study shows that long wave visible light does not 
induce significant changes in apoptosis, p53 and phosphorylated c-Jun expression. 
However, a significant increase in perinuclear vacuolization was seen. Perinuclear 
vacuolization is well known to dermatopathologists as an artefact in cryo embedded 
sections. We however discovered this significant phenomenon in paraffin embedded 
sections. In the present blinded histological assessment this phenomenon proved to
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be a real hallmark for the exposure to high dose of long wave visible light. Several 
authors have reported similar findings in UV irradiated skin, but did not discuss its 
significance (17,18). It can be postulated that this phenomenon in UV irradiated skin 
is seen as a transitional stage in the process from viable keratinocyte to apoptosis, 
which eventually result in clearly visible sunburn cells and additional p53 and 
phosphorylated c-Jun expression. It is still unclear what the significance of this 
phenomenon is as it was not accompanied by apoptotic cells, additional p53 and 
phosphorylated c-Jun expression. We however cannot entirely rule out the possibility 
of a heat-induced effect. Our volunteers did describe the exposure as comfortable, 
and in one individual slight heat erythema was visible once after an exposure. Our 
control for elastin and MMP-1 stainings was skin taken from a patient who received 
prolonged exposure in an UVA-1 phototherapy cabin, about 30 minutes after the 
last treatment. These paraffin sections did not show perinuclear vacuolization. In 
our experience, temperature rises considerably during this treatment even to an 
uncomfortable level. So it is unlikely that perinuclear vacuolization is heat-induced. 
Nowadays UVA-1 is used for the treatment of morphea, due to the accelerated 
degradation of intercellular matrix. This is marked by elastin fiber fragmentation 
and elastosis, collagen degradation and MMP-1 and c-Jun induction (19,20). C-Jun 
induction leads to Activator Protein-1 production, which in turn activates several 
matrix metalloproteinases (8 ). It was attractive to speculate whether high dose long 
wave visible light, with the advantage of a greater penetration depth due to its longer 
wavelength, could have similar effects as UVA-1. To prevent possible bias by age 
and smoking related induction of these markers, we exclusively included long-term 
non-smoking volunteers under the age of 40 years in the present study (19,21,22). 
Minimal MMP-1 expression was seen at all time points in dendritic cells in the 
dermis, however we did not observe significant changes in expression. There was no 
expression of phosphorylated c-Jun. Both results indicate that activation of degrading 
enzymes was not present. This is also confirmed by the elastin fiber staining which did 
not show changes during our study. We did not check for Tissue Inhibitors of Matrix 
Metalloproteinases (TIMPs) as a change in TIMP concentrations would probably 
not affect the detected minimal MMP-1 levels significantly. In conclusion high dose 
visible light phototherapy is no viable option in the treatment of sclerodermiform 
diseases.
Some studies have shown that visible light can induce immediate pigment darkening 
and melanogenesis (15,16). These studies however always included the UVA and 
near UVA spectrum, which can be expected to result in some immediate pigment 
darkening and melanogenesis. Our study shows that melanogenesis is not induced by 
long wave visible light.
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2.3.6 Conclusion
The present study shows that high dose long wave visible light at doses as used in PDT 
does not cause epidermal and dermal DNA damage, inflammation, melanogenesis 
and early photoageing parameters. The only sign of a photobiological effect was 
a significant increase in epidermal perinuclear vacuolization. This perinuclear 
vacuolization, however, did not result in apoptosis.
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Chapter 3
3.1 Adalimumab, a fully human anti-TNF-a monoclonal antibody 
(MoAb), treatment does not influence experimental UV response in 
the skin of rheumatoid arthritis patients.
3.1.1 Abstract
Background TNF-a is known to play an important role in UV induced 
immunomodulation and photodamage. It plays a role in UVB mediated induction of 
apoptosis and is a strong inducer of the JNK pathway, which eventually leads to the 
loss of dermal collagen and elastin content. Recently chimeric anti-TNF-a has been 
introduced as a therapy for rheumatoid arthritis.
Objectives The aim of the present study is to investigate the effect of anti-TNF-a 
treatment on UV induced DNA damage, apoptosis, and induction of matrix metallo 
proteinases.
Patients/Methods Twelve patients with rheumatoid arthritis were included and 
irradiated with 2 MED broad band UVB before and after administration of 0.5 mg/kg 
anti-TNF-a monoclonal antibody. Twenty-four hours after irradiation biopsies were 
taken. Frozen and paraffin sections were stained for p53, c-Jun, phosphorylated c- 
Jun, sunburn cells and MMP-1.
Results No significant changes were observed in the expression of p53 and sunburn 
cells and MMP-1 content after treatment with anti-TNF-a, whereas a slight but 
significant decrease in c-Jun and phosphorylated c-Jun expression was noted 
(p=0.0250 and p=0.0431 respectively).
Conclusions Our results show no influence of anti-TNF-a at therapeutic doses on the 
UV response in patients with rheumatoid arthritis.
3.1.2 Introduction
Irradiation with UVB (290-320 nm) is known to have acute and chronic effects on the 
skin. Acute effects of UVB encompass inflammation, DNA damage and DNA repair 
mechanism as well as apoptosis ("sunburn cells"). Chronic effects of UVB are photo 
ageing and carcinogenesis.
In vitro and in vivo studies have shown that a spectrum of cytokines is induced by 
UVB irradiation (1-6). TNF-a is a proinflammatory cytokine which has been shown 
to play a pivotal role in UVB induced inflammation and apoptosis. TNF-a is released 
by keratinocytes following UVB irradiation of the skin. Moreover, in vitro studies 
have shown that blocking TNF-a results in reduced expression of DNA damage 
markers and the number of apoptotic keratinocytes significantly (2,3,7-9). Although 
UV carcinogenesis was not found to be enhanced in knockout mice deficient for 
TNF-a receptors, inhibition of apoptosis in the skin after blocking TNF-a might
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have consequences for the clinical use of such treatment (10). Therefore, it is of 
importance to investigate whether anti-TNF-a is capable of inhibiting apoptosis in 
humans in vivo.
In animal studies and in keratinocyte cultures both TNF-a (11) and UVR (12) 
induction have shown to induce c-Jun and phosphorylated c-Jun (13,14). The 
transcription factor AP-1, which is the complex of c-Jun and c-Fos is also induced by 
UVR (15). TNF-a plays an important role in the prolonged activation of AP-1, due 
to its effect on the c-Jun kinases (14). Although the role of c-Jun and phosphorylated 
c-Jun in relation to apoptosis remains unclear, it is generally accepted that c-Jun and 
c-Fos play an important role in photoaging.
AP-1 induces the expression of several matrix metalloproteinases (MMPs) such as 
gelatinases, collagenases and stromelysin (16-19).
Chronic exposure to these MMPs result in wrinkles and skin ageing due to loss of 
collagen and increase in the elastin fragmentation of the skin (20-25). Up to date, the 
effect of anti-TNF-a treatment on the expression and activation of c-Jun, c-Fos and 
matrix metalloproteinases in human skin has not been studied.
Chimeric anti-TNF-a monoclonal antibodies (e.g. antibodies containing both 
human and mouse amino acid sequences) and TNF receptor constructs have now 
been registered for rheumatoid arthritis (RA), juvenile chronic arthritis and Crohn's 
disease. Interestingly, these therapies have also impressive effects on the skin lesions 
of patients with psoriatic arthritis. This opens the possibility of the future use of TNF 
neutralisation in inflammatory skin diseases.
Our centre participates in clinical trials with a new fully human, and potentially less 
immunogenic, anti-TNF-a antibody (adalimumab, D2E7, Knoll) in patients with RA. 
The efficacy and safety of this compound have been extensively demonstrated (26) 
and this agent is now undergoing phase III studies. (27-32)
In this paper, the responsiveness of the skin to UVB challenge was assessed before and 
two weeks after the first administration of adalimumab, in patients with active RA. 
This time schedule seems warranted since a single administration of this compound 
results in a clear clinical improvement and in a reduction of the acute phase reaction 
within days.
The aim of the present study was to investigate to what extent UVB irradiation effects 
are influenced by treatment of anti-TNF-a in vivo. We mainly focused on apoptosis, 
c-Jun/phosphorylated c-Jun and MMP-1 induction. The potential impact of these 
effects on carcinogenesis and skin aging are discussed.
3.1.3 Methods 
Patients and UVB irradiation
Twelve consenting patients with longstanding refractory RA according to the revised
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ARA criteria (1987) and active disease were recruited for this study (33,34). Patients 
underwent a 4-week washout period for disease modifying antirheumatic drugs 
(DMARD) and were on stable doses of NSAIDs and/or prednisone during the study. 
Patients had to have skin type II and III. The UVB irradiation was performed in a 
Waldmann UV 7001 K phototherapy cabin. Minimal Erythema doses (MED) were 
assessed before as well as two weeks after a single subcutaneous administration of the 
anti-TNF-a monoclonal antibody (0.5 mg/kg, Knoll AG, Ludwigshafen, Germany). 
Subsequently, these patients received a single dose irradiation of 2 MED broad band 
UVB (290-320 nm) on the buttocks. Three mm punch biopsies were obtained from 
unirradiated skin and the UVB exposed area at 24 hours after irradiation under local 
anaesthesia with 1% Xylocain and Adrenalin. UVB irradiation and biopsy procedures 
were repeated two weeks after the administration of the anti-TNF-a antibody (table 
3-1). Biopsies were snap frozen in Tissue Tek OCT compound (Miles Scientific, 
Naperville, USA) or embedded in paraffin after a 4-hour fixation in formaldehyde. 
The study was approved by the ethical committee of the University Medical Centre 
Nijmegen, the Netherlands.
Table 3-1: Study schedule 
administration
regarding UVB irradiation, biopsies and anti-TNF-a
Time Action
T = 0 First MED UVB assessment
T = 24 Biopsies from 2 MED irradiated skin and unirradiated skin
T = 48 Subcutaneous administration of 0.5 mg/kg anti-TNF-a
T = 2 weeks after anti-TNF-a 
administration
Second MED UVB assessment
T = 2 weeks + 24 hours Biopsies from 2 MED irradiated skin
Minimal erythema dose assessment
MED was defined as the UVB dose required to achieve a just perceptible erythema 24 
hours after irradiation (35). Six circular areas of 2.5 cm in diameter located horizontally 
just above the buttocks were irradiated with increasing doses of broadband UVB. For 
patients with skin type II, the following UVB range were used: 0.05-0.09-0.12-0.16­
0.20-0.27 J/cm2 and for skin type III: 0.05-0.10-0.15-0.20-0.30-0.40 J/cm2.
Monoclonal Antibodies
The following monoclonal antibodies were used: Monoclonal Murine anti-Human 
(wild type and mutant) p53 protein (1:200) (Dakopatts, Glostrup, Denmark), C-jun 
(1:50) and PhosphoPlus c-jun (Ser63) II (1:50) Antibody kit (New England Biolabs 
Inc., Beverly, MA, USA), which detects phosphorylation on point 63 of c-Jun and
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monoclonal anti-human MMP-1 (1:15) (Oncogene). HE stainings were performed to 
evaluate epidermal UV induced damage.
Immunohistochemical staining
Six |im paraffin sections were dewaxed with histosafe (Adamas, Amerongen, the 
Netherlands), and dipped in a series of graded ethanol from 100% to 50% and 
rehydrated in demineralized water. The slides were pre-treated in a 10 mM citrate 
buffer (high temperature microwave retrieval technique by Cattoretti (36)) at 450 W 
in a microwave oven for approximately 9 minutes and left to cool for 45 minutes. The 
slides were then air dried and immersed in a phosphate buffered saline (PBS).
For p53 this initial step was followed by incubation for 15 minutes with 20% 
normal horse serum (Vector Laboratories, Burlingame, USA) in 1% bovine serum 
albumin (BSA, Organon Technika, Boxtel, the Netherlands) in PBS and then by 
1 hour incubation with the p53 antibody (1:200). The slides were washed in PBS 
and incubated with rabbit anti-mouse biotinylated IgG (ABC kit-mouse, Vector 
Laboratories, Burlingame, USA) for 30 minutes. For c-Jun and phosphorylated c-Jun 
the initial step was followed by incubation for 15 minutes in 20% normal goat serum 
(Vector Laboratories, Burlingame, USA) and by 1 hour incubation with the anti-c-Jun 
or anti-ser73-phosphorylated c-Jun antibody (1:50). The sections were washed again 
in PBS and incubated with anti-rabbit biotinylated IgG for 30 minutes.
All the slides were washed in PBS and incubated with avidin biotin complex solution 
(ABC kit-mouse, Vector Laboratories, Burlingame, USA) for 30 minutes and labelled 
with metal enhanced DAB substrate (Pierce, Rockford, USA) for visualisation.
All slides were counter-stained with Mayer's haematoxylin (Sigma, St. Louis MO, 
USA) and after dehydration with 100% ethanol and histosafe mounted in Permount 
(Fisher Scientific, New Jersey, USA).
MMP-1 staining was done on 7 ^m cryostat sections fixed in 100% acetone following 
the above mentioned procedure, starting with the first incubation. After counter- 
staining the sections were mounted in glycerol-gelatin.
Histological examination
The histological examination was performed blindly by a single observer. Apoptosis 
was quantified as the number of sunburn cells in the epidermis and MMP-1 as the 
number of positive cells in the dermis both on a semi-quantitative scale (0 : none 
present, 1: minimal, 2: moderate and 3: pronounced amount). Photodamage was 
measured by counting the number of p53, c-Jun and phosphorylated c-Jun positive 
nuclei per mm length of section.
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c-Jun and phosphorylated c-Jun
□ Total c-Jun □  Phosphorylated c-Jun
non
irradiated
Figure 3-1 C-Jun and phosphorylated c-Jun expression in untreated and unchallanged skin 
and before and after 2 weeks treatment with anti-TNF-a in UVB challanged skin (mean ±
SEM)
Statistical evaluation
The data have been analysed using the SPSS Statistical package. Data are expressed as 
means ± SEM. For statistical analysis Wilcoxon matched pairs tests were performed. 
A p-value < 0.05 was considered significant.
Figure 3-2 Immunohistochemistry showing c-Jun expression in untreated and unchallenged 
skin (A) and before (B) and after (C) 2 weeks treatment with anti-TNF-a in UVB challanged
skin
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p53
Time
Figure 3-3 p53 expression in untreated and unchallanged skin and before and after 2 weeks 
treatment with anti-TNF-a in UVB challanged skin (mean ± SEM)
3.1.4 Results 
Minimal Erythema Dose
MEDs ranged from 0.10 J/cm2 to 0.30 J/cm2. The MEDs before and 2 weeks after the 
subcutaneous administration of the anti-TNF-a antibody did not differ significantly 
(p=0.5), the medians being 0.15 J/cm2 and 0.16 J/cm2 respectively.
HE staining for sunburn cells
A significant rise in sunburn cells (SBC's) count was seen after irradiation (p=0.03), 
but no significant difference was seen after treatment with the anti-TNF-a antibody 
(p=0.50).
Markers for DNA damage
All markers (p53, c-jun and phosphorylated c-jun) showed a significant increase 
in expression after UVB irradiation (p=0.0076 for all three markers). C-Jun and 
phosphorylated c-Jun showed a significant but slight decrease in expression after 
treatment with anti-TNF-a (p=0.0250 and p=0.0431 respectively, figures 3-1
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Sunburn cell and MMP-1
□ Sunburn cells □  MMP-1
Untreated non Untreated Treated 
irradiated
Figure 3-4 Sunburn cells and MMP-1 expression in untreated and unchallanged skin and 
before and after 2 weeks treatment with anti-TNF-a in UVB challanged skin (mean ± SEM)
and 3-2). Initially, after UV exposure, expression of c-Jun and phosphorylated c- 
Jun is observed in the upper layers of the epidermis (stratum granulosum). After 
administration of the anti-TNF-a antibody there seems to be a slight shift towards the 
stratum spinosum.
P53 expression did not change significantly after treatment with the anti-TNF-a 
antibody.
Matrix Metallo Proteinase -1
Before irradiation there was a minimal staining of MMP-1 positive cells in the upper 
dermis, which increased significantly (p=0.003) after irradiation with broad band 
UVB. There was no significant change in MMP-1 expression after the administration 
of the anti-TNF-a (p=0.735)
3.1.5 Discussion
The dosage of anti-TNF-a, as used in the present study, was set by an optimal 
therapeutic effect in rheumatoid arthritis. Indeed 7 out of 12 patients fulfilled clinical 
response criteria after two weeks. In contrast, the effect of anti-TNF-a administration 
on UV induced skin inflammation was negligible; showing no change of minimal
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erythema dose scores before and after treatment with anti-TNF-a (0.15 ± 0.04 
J/cm2 and 0.16 ± 0.07 J/cm2). A recent study showed that NSAIDs can reduce the 
UV induced erythema and in vitro even result in reduced production of TNF-a and 
several cytokines. In our study however, erythema was induced, although the patients 
were on stable doses of NSAIDs and/or prednisone. Minimal erythema doses were 
comparable with earlier published doses for comparable skintypes. It is feasible that 
NSAID doses applied in vivo did not reach enough skin penetration compared to the 
direct application of NSAIDs on HACAT cells.
The present in vivo study provides additional evidence of the safety of the use of anti- 
TNF-a in patients with severe inflammatory diseases like rheumatoid arthritis. Anti- 
TNF-a treatment did not influence the UVB induced skin response significantly, as 
markers for photo damage and early markers for photo aging are not or only slightly 
changed after UVB irradiation and anti-TNF-a treatment. Only the induction of c-Jun 
and phosphorylated c-Jun is slightly but significantly decreased after treatment with 
the antibody. Especially the decrease in phosphorylated (active) c-Jun was almost 
negligible due to the use of a semiquantitative scoring method. It was however 
attractive to speculate if the in-vivo inhibition of these parameters might be reflected 
in a decreased induction of matrix metalloproteinases (MMPs) in the skin, which in 
the long term might result in less photo aging in sun exposed subjects or decrease 
in apoptosis. MMPs also play an important role in the degeneration of cartilage 
in rheumatoid arthritis resulting in increased expression of MMP-1 and MMP-3 
concentrations in serum. This study clearly shows that MMP-1 expression in the skin 
after UVB irradiation is not affected by the anti-TNF-a treatment, this in spite of 
the fact that MMP-1 and MMP-3 concentrations in serum decreased significantly 2 
weeks after the first administration of anti-TNF-a (37).
It has been shown that anti-TNF-a reduces the number of apoptotic cells after UVR 
exposure in keratinocyte cultures and shaved Balb/c-mice (9). However, in these 
studies anti-TNF-a had been added immediately after the UV challenge. Based on the 
present study, it is too early to exclude entirely an effect of anti-TNF-a on apoptosis 
in humans in vivo, although a sustained inhibition of apoptosis has been ruled out.
It is attractive to speculate why anti-TNF-a treatment does not influence these 
partly TNF-a mediated processes. As most of our patients did improve remarkably 
from their rheumatoid arthritis it is likely that the antibody did work. One may 
hypothesize that skin penetration of the antibody is impaired. This however seems 
unlikely because of the remarkable effects of anti-TNF-a treatment in psoriasis and 
arthritic psoriasis patients. The anti-TNF-a antibody seems to accumulate in areas 
with extremely enhanced TNF-a expression. In our patients this area were the joints 
instead of the skin.
In conclusion, the present study demonstrates that, except for a slight but 
significant decrease in c-Jun and phosphorylated c-Jun, anti-TNF-a treatment does 
not significantly influence our UVB induced photo response model in the skin of
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rheumatoid arthritis patients. Further studies are however indicated to study the long­
term effects of anti-TNF-a on skin ageing and carcinogenesis and in inflammatory 
skin conditions.
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Chapter 4
4.1 The treatment op vitiligo vulgaris with narrow band uvb (311 
nm) for one year and the effect of addition of folic acid and vitamin 
B12
4.1.1 Abstract
Narrow band UVB is succeeding PUVA as the main treatment of vitiligo vulgaris in 
several European countries. Deficiency states for vitamin B12 and folic acid in some 
vitiligo patients have prompted researchers to look into the efficacy of these vitamins 
in the treatment of vitiligo. In the present controlled study we investigated the value 
of narrow band UVB phototherapy in the treatment of vitiligo and the possible 
additive effect of vitamin B12 and folic acid.
Twenty-seven patients with long-term stable vitiligo were included and randomised 
in an 'UVB only' (UVB) or 'UVB combined with vitamin B12 and folic acid' (UVB+) 
group. Patients were irradiated thrice weekly for one year, whilst repigmentation 
was carefully monitored. In 92% (25/27) of the patients up to 100% repigmentation 
was seen. Repigmentation was notable in lesions on the face, neck and throat, lower 
arm, chest, back and lower legs, whilst repigmentation on hands and wrists and feet 
and ankles proved to be minimal. Maximum repigmentation rates did not differ 
significantly between the UVB group and the UVB+ group.
Our study reconfirms that narrow band UVB phototherapy is an effective treatment 
for vitiligo and shows that co-treatment with vitamin B12 and folic acid does not 
improve the outcome of treatment of vitiligo with narrow band UVB phototherapy.
4.1.2 Introduction
Vitiligo has been known for centuries and is a disease characterised by white patches, 
due to a loss of melanocytes (1,3). Although several treatments were suggested 
during the ages, it was not until the 1900's that the first effective treatment was found, 
photochemotherapy (4,6). Psoralen and UVA irradiation (PUVA) treatment has been 
the only successful treatment for decades and in some countries PUVA still is the 
main treatment for generalised vitiligo. Recently, new advances in phototherapy 
have provided new treatment possibilities. Especially narrow band UVB has been 
a major breakthrough and is succeeding PUVA as the main treatment in several 
countries (7,8). So far, however, controlled studies on the efficacy of narrow band 
UVB are not available. It should be taken into consideration that UVB therapy only 
is effective after prolonged treatment and that long-term placebo-controlled studies 
for approaches where ample evidence is available are difficult to justify. In order to 
further substantiate the evidence for the efficacy of long-term narrow band UVB 
therapy, a study in patients with longstanding stable vitiligo is of importance.
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Research into the aetiology and pathomechanisms of vitiligo has provided some 
insight in the biochemical pathways involved. This resulted in the development 
of combined treatments of phototherapy with several biochemical compounds as 
pseudocatalase, calciumchlorid and phenylalanine (9,14).
It has been suggested that vitamin B12 and folic acid may play a role in the 
melanin synthesis pathway, as the pteridine part of folic acid and N-N-methylene 
tetrahydrofolate as well as the vitamin B12 dependent formation of methionine could 
interfere with processes leading to depigmentation and pigmentary dilution (15,17). 
Several reports suggest that a deficiency of vitamin B12 and folic acid can be a 
common characteristic of vitiligo, while others contradict them (18,20). Therefore 
it is attractive to hypothesise that vitamin B12 and folic acid may contribute to the 
efficacy of phototherapy in vitiligo.
The aim of the present study is to confirm the therapeutic value of narrow band UVB 
in the treatment of patients with stable vitiligo and secondly to evaluate the additional 
effect of vitamin B12 and folic acid on the treatment of vitiligo vulgaris with narrow 
band UVB phototherapy using a non-blinded approach comparing UVB and vitamin 
B12 and folic acid with narrow band UVB.
4.1.3 Material & methods 
Patients
Twenty-seven patients, male and female, age 18 and above, with stable vitiligo vulgaris 
(at least 1 year no changes) and Fitzpatrick's skintype II-IV from our outpatient clinic 
were included in the study, after written informed consent had been obtained. Patients 
using any medical treatment for their vitiligo at the moment were excluded. Other 
exclusion criteria were patients with a history of skin cancer or dysplastic naevus 
syndrome, photosensitivity or use of photosensitising medicines, psychiatric or 
epileptic disorders, known renal failure and known allergies to substances in the trial 
medication. Table 4-1-1 shows their demographic data.
Treatments
The patients were randomised in two narrow band UVB treatment groups. The first 
group only received narrow band UVB phototherapy, the second group received 
twice daily vitamin B12 (cobalamin) 1000 g sustained release tablets (Orthica B.V., 
Weesp, the Netherlands) and folic acid 5 mg tablets (Dumex, the Netherlands). 
These doses were chosen in concordance with a previous study by Juhlin & Olsson 
(21). Both groups were irradiated with narrow band (311 nm) UVB as generated by 
Philips TL-01 lamps in a Waldmann 7001 cabin (Waldmann Medical Technology, the 
Netherlands). Irradiation was given 3 times weekly for 12 months and started with
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0.10 J/cm2 exposure, which increased with 0-30% every next visit on an individual 
basis.
Table 4-1-1: Patient characteristics
Characteristics Control group Vitamin group
No. of patients 13 14
Skin type II 5 3
Skin type III 7 10
Skin type IV 1 1
Age mean ± SD (Range) 41.6±8.7 (20-51) 46.8±10.2 (29-68)
Sex, M/F 6/7 5 / 9
Duration of disease 
mean ± SD (Range)
10.8±9.9 (1-30) 18.3±13.1 (1-47)
Percentage of body 
surface affected mean ± 
SD (Range)
8.4±5.6 (2-18) 10±7.5 (3-26)
All the vitiligenous areas were carefully monitored monthly during the study 
period, including before and after photographs. The percentage of repigmentation 
was visually estimated in all areas. As primary efficacy criterion we selected the 
areas showing the most active repigmentation. This was designated as "maximum 
repigmentation".
Treatment was continued for one year after start of phototherapy or discontinued 
earlier if full repigmentation was reached before that.
Treatment outcome was visually scored as the percentage of repigmentation of 
depigmented lesions.
Statistical analysis was performed with a one way ANOVA test on SPSS 7.5 for 
Windows.
4.1.4 Results
The mean cumulative dose of narrow band UVB given to each patient was 126.68 ± 
88.64 J/cm2 (11.6-401.76 J/cm2). Twenty-five of the 27 patients showed prominent 
repigmentation on most lesions of the body. In each group one patient showed less 
than 5% repigmentation after 4 months of phototherapy and these patients were 
advised to discontinue phototherapy treatment.
As shown in Table 4-1-2 more than 90% repigmentation (median values) is reached 
on the face, neck and throat, lower arm, chest, back and lower legs, while less than 
25% repigmentation (median values) is seen on the hands and wrists and feet and 
ankles. Fig. 4-1-1 shows the maximum repigmentation in vitiligenous lesions for 
both groups.
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Max repigmentation
Narrow band UVB A Narrow Band UVB and medication
Time (months)
Figure 4-1-1 Course of maximum repigmentation during one year narrow band UVB 
phototherapy with (0) or without (▲) medication.
Table 4-1-2: Percentage of repigmentation in different body areas of all the patients
Area Number of 
patients
Repigmentation (%) 
Mean ± SD
Repigmentation 
Median (Range)
Face 19 71.8 ± 35.5 90 (5-100)
Neck/Throat 7 68.6 ± 40.7 90 (5-100)
Upper Arm 4 65.0 ± 31.0 65 (30-100)
Elbow 12 50.4 ± 29.8 45 (10-100)
Lower Arm 7 80.0 ± 24.5 90 (30-100)
Hand/Wrist 18 35.6 ± 31.5 22.5 (10-100)
Axilla 17 37.4 ± 31.9 40 (0-100)
Chest 9 71.1 ± 35.9 90 (20-100)
Abdomen 3 80.0 ± 10.0 80 (70-90)
Back 10 84.0 ± 27.5 92.5 (10-100)
Groin 14 70.4 ± 25.5 77.5 (20-100)
Upper Leg 6 55.0 ± 40.9 70 (0-100)
Knee 5 62.0 ± 41.5 80 (0-100)
Lower Leg 12 85.0 ± 16.1 90 (60-100)
Foot/Ankle 12 12.1 ± 10.8 10 (0-40)
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No significant difference in repigmentation was reached at any of the monthly 
measurement points between the two groups (p > 0.175). No additional effect of 
vitamin B12 and folic acid on repigmentation was seen either on less responsive areas 
like the hands and feet (p > 0.23).
Fig. 4-2-2 shows an example of an average response on a patient treated with UVB 
phototherapy alone. In all patients transient erythema was observed occasionally, 
usually experienced as localised prickling of the skin within 24 hours after irradiation. 
However these responses were mild and never induced aggravation of the lesions 
(Koebner phenomenon).
4.1.5 Discussion
So far no standardised scoring method for evaluating the effect of repigmentation 
therapies is available. A PASI like score, as used for psoriasis, would be a great step 
forward to evaluate and compare the effect of repigmentation between different 
therapies. Some studies use a rather inaccurate graded scoring method (less than 30%, 
30-70% and more than 70% repigmentation, or total, partial and no repigmentation) 
(7,22,25). Our study shows that only slight repigmentation or no repigmentation at 
all was seen on the dorsa of hand and feet and the inner wrist, while other areas like 
the face, chest, extensor surfaces of the lower arm and leg, back and neck/throat 
often repigment rather easily and completely (Fig. 4-1-2 and Table 4-1-2). Previously 
resistance of hands and feet and the inner wrist has been suggested for PUVA 
phototherapy, although this study did not provide a systematic quantitative analysis 
(25). On the other hand some studies claim to achieve full repigmentation, again not 
specifying the responses per body region ( 1 0 ).
In view of the substantial intra individual variability, we have avoided the pitfall 
of a general score and instead chosen for the approach of scoring repigmentation
Figure 4-1-2 Before and after photographs of a vitiligenous area on the lower arm and wrist of 
a patient. Note the minimal repigmentation on the elbow and wrist. Patient was treated with 
narrow band UVB alone. Photographs were taken with an interval of 12 months.
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visually per lesion and to select retrospectively the maximum repigmentated area 
in each patient as the primary efficacy criterion. As additional efficacy criterion we 
used the repigmentation in all body areas. A modified Psoriasis Area Severity Index 
(PASI) score, with special attention to less responding areas, possibly assisted with 
computerised measurement of the total reduction in vitiligenous areas could have 
provided more insight in the efficacy of vitiligo treatments.
Although no large studies and no controlled studies have been done, narrow band 
UVB has been proven in some studies to be effective in inducing repigmentation in 
patients with vitiligo (8,23,26). Our study shows that narrow band UVB treatment 
results in an up to 100% repigmentation of depigmented lesions in 92% (25/27) 
of patients with long-term stable vitiligo vulgaris. During this treatment period no 
relapse was seen and besides some prickling sensations usually on depigmented areas 
of the skin and occasional phototherapy induced erythema no major side effects were 
seen.
There have been reports that folic acid and vitamin B12 can play an indirect role in 
repigmentation. Both substances have been indicated in being able to supplement 
deficiency states of tyrosine and methionine, which have been regarded as possible 
mechanisms for depigmentation in vitiligo and pigmentary dilution as seen in 
homocysteinuria (21). Others report possible deficiencies of folic acid and/or vitamin 
B12 in vitiligo patients (18,20), however recently a large controlled study by Kim et 
al. did not show any difference in serum levels compared with a normal control group 
(19). This is in concordance with previous findings by Juhlin & Olsson (21). We 
therefore decided not to measure serum levels of these compounds in our patients. 
The study by Juhlin & Olsson showed an improvement of vitiligo with solar UV 
exposure when combined with vitamin B12 and folic acid (21). This study however 
did not include a control group and was conducted without standardised UV 
exposure.
The present study reconfirms the efficacy of narrow band UVB phototherapy in 
vitiligo but did not show any advantage of the addition of vitamin B12 and folic 
acid.
A possible explanation for the discrepancy between the studies could be that we have 
used an optimal dose of narrow band UVB for a long period of time, which by its 
high efficacy hides any effect of vitamin B12 and folic acid and which are thus not 
needed.
Acknowledgements
We would like to thank Orthica B.V. for the supply of the vitamin B12 tablets.
83
Chapter 4
Reference List
1. Hann SK, Chung HS: Historic view of vitiligo in Korea. Int J Dermatol 1997;36:313-315.
2. Lee S: Vitiligo auf ein historischen Porträt. Hautarzt 1982;33:335-336.
3. Singh G, Ansari Z, Dwivedi RN: Letter: Vitiligo in ancient Indian medicine. Arch Dermatol 
1974;109:913
4. Benedetto AV: The psoralens. An historical perspective. Cutis 1977;20:469-471.
5. Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C, Gillespie L, Brown D, Gasparro 
FP: Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J 
Dermatol Sci 1999;19:78-88.
6. Grimes PE: Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997;15:921-926.
7. Westerhof W, Nieuweboer-Krobotova L: Treatment of vitiligo with UV-B radiation vs topical 
psoralen plus UV-A [see comments]. Arch Dermatol 1997;133:1525-1528.
8. Njoo MD, Bos JD, Westerhof W: Treatment of generalized vitiligo in children with narrow­
band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000;42:245-253.
9. Schallreuter KU, Wood JM, Berger J: Low catalase levels in the epidermis of patients with 
vitiligo [see comments]. J Invest Dermatol 1991;97:1081-1085.
10. Schallreuter KU, Wood JM, Lemke KR, Levenig C: Treatment of vitiligo with a topical 
application of pseudocatalase and calcium in combination with short-term UVB exposure: a 
case study on 33 patients [see comments]. Dermatology 1995;190:223-229.
11. Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis N, Tsagaraki S, Stratigos J: Vitiligo 
therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol 1989;28: 
545-547.
12. Camacho F, Mazuecos J: Treatment of vitiligo with oral and topical phenylalanine: 6 years of 
experience [letter]. Arch Dermatol 1999;135:216-217.
13. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB: Phenylalanine and UVA light for 
the treatment of vitiligo. Arch Dermatol Res 1985;277:126-130.
14. Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W: L-phenylalanine 
and UVA irradiation in the treatment of vitiligo. Dermatology 1994;188:215-218.
15. Lerner AB, Fitzpatrick TB: Biochemistry of melanin formation. Physiol Rev 1950;30:91- 
126.
16. Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M, Lemke KR, Rodl W, Swanson NN, 
Hitzemann K, Ziegler I: Regulation of melanin biosynthesis in the human epidermis by 
tetrahydrobiopterin. Science 1994;263:1444-1446.
17. Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, Gutlich M: 
Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder 
vitiligo. Biochim Biophys Acta 1994;1226:181-192.
18. Banerjee AK, Banerjee DK, Chaudhury DS: Serum vitamin B12 level in vitiligo--a 
preliminary study. Bull Calcutta Sch Trop Med 1970;18:73-75.
19. Kim SM, Kim YK, Hann SK: Serum levels of folic acid and vitamin B12 in Korean patients 
with vitiligo. Yonsei Med J 1999;40:195-198.
20. Montes LF, Diaz ML, Lajous J, Garcia NJ: Folic acid and vitamin B12 in vitiligo: a nutritional 
approach. Cutis 1992;50:39-42.
84
Narrow band UVB phototherapy for vitiligo
21. Juhlin L, Olsson MJ: Improvement of vitiligo after oral treatment with vitamin B12 and folic 
acid and the importance of sun exposure. Acta Derm Venereol 1997;77:460-462.
22. Kim HY, Kang KY: Epidermal grafts for treatment of stable and progressive vitiligo. J Am 
Acad Dermatol 1999;40:412-417.
23. Nieuweboer-Krobotova L, Westerhof W: [Treatment of vitiligo with UVB (311 nm) vs 
topical PUVA]. Ned Tijdschr Derm Ven 1997;7:95-97.
24. Orecchia G, Perfetti L: Photochemotherapy with topical khellin and sunlight in vitiligo. 
Dermatology 1992;184:120-123.
25. Ortel B, Tanew A, Honigsmann H: Treatment of vitiligo with khellin and ultraviolet A [see 
comments]. J Am Acad Dermatol 1988;18:693-701.
26. Scherschun L, Kim JJ, Lim HW: Narrow-band ultraviolet B is a useful and well-tolerated 
treatment for vitiligo. J Am Acad Dermatol 2001;44:999-1003.
85
Chapter 4
4.2 Quality of life in vitiligo patients after treatment with long­
term narrow band UVB phototherapy
4.2.1 Abstract
Long term treatments for chronic diseases like vitiligo need to be evaluated for their 
clinical efficacy. Assessment of the quality of life, however, may provide the most 
relevant information on the actual benefit for these patients. In this study we evaluated 
quality of life after long-term narrow band UVB for the treatment of vitiligo.
All patients, with long-term stable vitiligo vulgaris, who were treated at our clinic 
during the last four years received a specifically for this study designed Quality of 
Life questionnaire, which included questions about general wellbeing, camouflage 
and psychosocial aspects. 71.4% of the patients responded. Most patients indicated 
an improvement on a psychological level, but an increase in camouflaging.
The present study shows that, after long-term narrow band UVB phototherapy, skin 
appearance does not play a major role in the life of vitiligo patients, while well being 
only improved in a minority of patients.
4.2.2 Introduction
Vitiligo is a disease characterised by loss of melanocytes, resulting in depigmentation 
of skin and hair. Vitiligo can be a socially disabling disease, which affects quality of 
life.
Aetiology and pathogenesis are still largely unknown. Treatments can be classified in 
four main groups: Topical corticosteroids, phototherapy, melanocyte transplantation 
and camouflage. Good clinical results have been achieved with narrow band UVB 
phototherapy (1,2). In general, treatment has to be given 2-3 times weekly for about 2 
years to achieve a substantial repigmentation of affected areas. However, some areas, 
such as the hands and feet are recalcitrant to these treatments and full repigmentation 
of these areas is rare (in press). Treatment results can be expressed in terms of degree 
of repigmentation. However, assessment of quality of life will provide the most 
relevant information on the actual benefit of a treatment in patients with chronic 
diseases such as vitiligo.
The most important feature of quality of life measurements is that it is only an 
indication of the quality of life at the time-point the measurement is taken. Several 
general validated instruments have been introduced like the General Health 
Questionnaire (GHQ) (3), Medical Outcomes Study 36-item Short-Form Survey 
(SF-36) (4) and other structured diagnostic interviews. Due to shortcomings in these 
instruments for the dermatological setting, several disease specific questionnaires 
were developed such as the Psoriasis Disability Index (5). Comparison between
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different skin diseases, however, is still not possible.
In 1994 Finlay and Khan proposed the Dermatology Life Quality Index (DLQI) (6 ) 
and in 1996 Chren et al. proposed the Skindex (7). The DLQI consists of 10 questions 
which focus on 7 aspects of quality of life (symptoms, feelings, daily activities, 
leisure activities, work or school, personal relationships and treatment), while the 
Skindex compromises 61 questions focusing on 8  aspects of quality of life (cognitive 
effects, social effects, physical limitations, physical discomfort, depression, fear, 
embarrassment and anger) (8,9). Recently the 61 questions version was shortened to 
a more practical 16 questions version ( 1 0 , 1 1 ).
QOL problems in vitiligo patients can be categorised in 6  major categories: choosing 
clothes, use of sunblocks, use of camouflage, avoidance of activities, reactions of 
others and emotional reactions (12). The DQLI addresses most of these aspects and 
is the easiest and most practical approach for questionnaires, although the Skindex is 
probably more accurate and detailed.
The best way to evaluate the QOL after a treatment is to take a baseline questionnaire 
(before treatment) and another after having finished the treatment. In the present 
study the patients were asked retrospective to compare their current QOL with 
the past. Therefore the outcome of the present study can only provide preliminary 
conclusions.
With the retrospective nature of our study in mind we developed a new and 
unvalidated quality of life questionnaire to evaluate the effects of long-term narrow 
band phototherapy UVB. We modified the DQLI to fit the retrospective nature of our 
study and added a few extra questions about camouflage and general wellbeing.
The aim of the present study was to investigate the effect of long-term narrow band 
UVB phototherapy on the quality of life in adult vitiligo patients.
4.2.3 Material & methods
All vitiligo patients who had received long-term narrow band UVB phototherapy 
during the last 4 years were approached to participate in an anonymous retrospective 
comparative quality of life questionnaire. During that 4 year period none of the 
patients had received psychological counselling and no attempts, besides clinically 
treating the vitiligo, were made to influence the quality of life. All patients received 
a letter explaining the study, a freepost return envelope and a questionnaire. The 
questionnaire (appendix I) consisted of 14 multiple-choice questions regarding 
general wellbeing and health (1-3), social and psychological aspects (4-12) and 
camouflage (13-14). The questions were scored on a Likert scale to evaluate the 
answers. The rule the higher the better applies here. A positive number (1 and 2) 
denotes an improved quality of life after long-term narrow band UVB phototherapy 
as compared with the situation before treatment, using retrospective analysis. The 
numbers -1 and -2 denote a deterioration of the situation. The number zero denotes no
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difference or that the question was not relevant/applicable for that patient.
The maximum score for the questionnaire is 28 points and the minimum -28. The 
maximum sum of points (cumulative for all respondents) per question is 2  times the 
number of respondents.
All data were collected and analysed using version 10.0 of the SPSS Statistical 
Analysis package.
4.2.4. Results
Forty-two patients with vitiligo, who were treated with long-term narrow band 
UVB phototherapy in our clinic during the past 4 years were approached. Thirty 
patients (71.4%) returned the questionnaire. The answers are displayed as means 
and cumulative sum scores (maximum score = 60) per question in table 4-2-1 and as 
cumulative sum scores (maximum score = 28) per patient in table 4-2-2.
Twenty-one out of these patients had a mean score above zero, which denotes 
an improvement. In 23.3% (7/30) a mean score above 1 was recorded, which is 
a significant improvement after phototherapy. The question about how patients 
evaluate their health had the best overall score with a mean of 0 .8 6 , while the last 
question about camouflage showed the lowest score with a mean of -0.3, which 
indicates that most people had to camouflage more after phototherapy treatment than 
before. Actually all, except the last question showed an overall score above zero (as 
shown in table 4-2-1).
Table 4-2-1: Mean and cumulative sum scores per questionO
Q4Q4
o
2Q1Q1nQtn 9Q98Q87
a
Q10 Q11 Q12 Q13 Q14
Mean 0.87 0.27 0.40 0.07 0.33 0.17 0.07 0.07 0.03 0.10 0.30 0.40 0.03
0.30
Sum 26 8 12 2 10 5 2 2 1 3 9 12 1 -9
The higher the better. Maximum mean score = 
score = 60 and minimum sum score = -60.
2 and minimum mean score = -2. Maximum sum
26.7% of the patients reported a cumulative sum score below zero (score -1 to -12), 
indicating a loss of quality of life to some degree, and 70 % reported an improvement 
(score 1 to 2 0 ), while 1 patient indicated that his quality of life was not affected by 
the phototherapy (shown in table 4-2-2).
General health was generally good (7 excellent, 18 good) with only a slightly 
improvement after phototherapy (3 much better, 3 slightly better, 22 comparable). 
The skin influences life less after phototherapy in 30% of the patients (7 much less, 2 
slightly less, 16 comparable).
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Table 4-2-2: Cumulative sum score per patient.
Case p i p2 p3 p4 P5 P6 p7 p8 p9 p10
Sum 6 1 10 8 2 1 1 1 -12 5
Case p11 p12 p13 p14 p15 p16 p17 p18 p19 p20
Sum -3 1 1 2 -2 11 -1 10 2 16
Case p21 p22 p23 p24 p25 p26 p27 p28 p29 p30
Sum -7 5 -3 -1 -6 1 20 8 7 0
The higher the better. Maximum sum score = 28 and minimum sum score = -28
Phototherapy had only a minor effect on the social level. Only 23.3 % noticed less 
influence on leisure activities after treatment, 13.3% had less problems with sports, 
6.7% with work or study, 6.7% with relationships, one person even had a better sex 
life after treatment. 16.7% had less problems with starting relationships or getting 
new friends. With respect to psychological aspects, only 16.7 % had less physical and 
emotional problems after phototherapy. 26.7% did feel less stared at by people, and 
36.7% had less negative feelings or felt insecure.
Interestingly 26.7% never had problem with sports, 43.3% never had problems with 
work or study, 43.3% never had problems with relationships or with starting new 
ones, 53.3% never had sexual problems due to their vitiligo (indicated question was 
not applicable). However, more people had to camouflage their lesions as 20.7% had 
to choose appropriate clothing compared with 17.2% who improved and even 30% 
needed more time to camouflage the lesions compared with only 1 0 % who needed 
less time to camouflage lesions.
4.2.5 Discussion
Quality of life research in vitiligo has always focused on the impact of the disease on 
social, psychological and physical wellbeing. As far as we know this is the first study 
to focus on the impact of treatment on the quality of life in adult patients with vitiligo. 
Njoo et al. have described the favourable effects of narrow band UVB on the quality 
of life in children with vitiligo before (13).
Quality of life and subjective assessment of the seriousness or extent of a disease is 
highly variable between patients. In our experience, especially in visible diseases 
like vitiligo, there seems to be a discrepancy between clinical diseases severity and 
a patients own experience. Due to this phenomenon, it is possible that minimal 
lesions could account for a serious impact on the quality of life. Furthermore, a slight 
improvement could result in a huge improvement of the quality of life. Therefore, 
we did not take the extent or severity of the vitiligo and the clinical efficacy of the 
treatment in account.
The present study showed a response rate of 71.4% and provides a representative
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impression of the study population. In fact the response rate of the present study is 
very high as compared with the 39% response of the mass questionnaire by Kent and 
Al-Abadie in 1996 in members from the UK Vitiligo Society (14,15). However, our 
study included only a small number of patients. Our response rate is similar to the
65-70% response rate in a questionnaire under patients who attended two vitiligo 
clinics (16).
The present study shows that QOL improves following long-term narrow band 
phototherapy as 70% of the patients had a mean score above zero, 23.3% had an even 
more pronounced improvement with mean scores above one.
Former QOL studies in vitiligo patients have always focused on the general QOL 
scores, without discussing separate items. Kent and Al'abadie however did describe 6  
items that influence vitiligo patients lives within 3 weeks preceding their questionnaire. 
They focused on choice of clothing, use of sunblocks, use of camouflaging make-up, 
avoidance of activities, reactions of others and emotional reactions. Our study shows 
that after narrow band UVB phototherapy, psychosocial items improved, while in 
other patients camouflaging and choice of clothes were negatively influenced. One 
of the major problems with phototherapy in vitiligo is that depigmented skin is not 
affected selectively, causing marked pigmentation of the uninvolved skin as well. 
Thus during phototherapy normal skin may tan easily in contrast to lesional skin 
which can result in increased contrast in skin colour and probably in a more increased 
use of camouflage cosmetics till full repigmentation is reached. Treatment resulted in 
smaller, but more visible lesions as commented by some patients. One other factor is 
that repigmentation is usually very limited on visible parts of the skin like dorsum of 
hands and feet. This could also explain the mean overall score of -0.3 for the question 
about the time needed for camouflaging.
A large group of our patients never had problems with their sex life (43.4%) or with 
work or studying (53.3%). It is remotely possible that some people who answered 'no 
change' did mean not applicable. In this case the percentages could change to 96.6% 
and 93.3% respectively. Similar responses were also seen in the study by Kent and 
Al'abadie, as none of their respondents noted these problems.
Patients generally rated their health as good to excellent, but phototherapy only 
accounted for a small improvement (20% of patients) in general wellbeing. An 
interesting finding was that after phototherapy, skin appearance influenced more 
(30% of patients) peoples' lives less negatively. Most people found that their health 
had improved after phototherapy. This seems to be in concordance with the fact 
that the cumulative sum score/question was 1 2  for the question about the extent of 
insecurity and negative feelings caused by the skin, which indicates a reduction in 
these feelings.
Due to the retrospective nature of this study it is not possible to rule out biasing 
phenomena like cognitive dissonance, as people tend to recall what they were like 
before very inaccurately. Longitudinal studies are warranted to study the effects of
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long term narrow band UVB on the quality of life.
4.2.6 Conclusion
This study using a non-validated QOL questionnaire (based on the DQLI) showed 
that skin appearance does not play a major role in the lives of vitiligo patients after 
narrow band UVB phototherapy (also indicated by reduced feelings of insecurity and 
negative feelings) and that only in a minority of patients general wellbeing improved. 
Furthermore phototherapy increased the necessity to camouflage. It should be noted 
that this study was performed shortly after completion of the phototherapy treatment. 
Long-term studies are warranted to correct for the increased contrast bias and to 
evaluate long-term effects on quality of life.
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Instruction: This questionnaire concerns your point of view on your health. With these questions we
Please answer every question by marking the answer in the appropriate mentioned way. If you are not
APPENDIX I 
Quality of life questionnaire
 
can evaluate a possible improvement in health status and social abilities.
 
sure how to answer the question, please give the best possible answer.
1. How would you generally rate your health?
(complete only one answer)
► Excellent .................................................................................................... 2
► Good ....................................................................................................1
► Moderate ...................................................................................................-1
► Poor ...................................................................................................-2
2. How would you generally rate your health now compared with before the phototherapy? 
(complete only one answer)
► Much better than before phototherapy ...................................... 2
► Slightly better than before phototherapy ...................................... 1
► Comparable with before phototherapy ...................................... 0
► Slightly worse than before phototherapy ..................................... -1
► Much worse than before phototherapy ..................................... -2
3. To what extent does your skin influence your life nowadays compared with before 
phototherapy?
(complete only one answer)
► Much less than before phototherapy ......................................2
► Slightly less than before phototherapy ......................................1
► Comparable with before phototherapy ......................................0
► Slightly more than before phototherapy .....................................-1
► Much more than before phototherapy .....................................-2
► Not relevant ................................................................................... 0
4. To what extent did your physical health and emotional problems inhibit your social activities 
with friends, family and others compared with before phototherapy?
(complete only one answer)
► Much less than before phototherapy ......................................2
► Slightly less than before phototherapy ......................................1
► Comparable with before phototherapy ......................................0
► Slightly more than before phototherapy .....................................-1
► Much more than before phototherapy .....................................-2
► Not relevant .................................................................... 0
5. To what extent does you skin influence your leisure activities negatively compared with 
before phototherapy?
(complete only one answer)
► Much less than before phototherapy .....................................2
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► Slightly less than before phototherapy  1
► Comparable with before phototherapy  0
► Slightly more than before phototherapy  -1
► Much more than before phototherapy  -2
► Not relevant  0
6. To what extent does your skin interfere with sports compared with before phototherapy? 
(complete only one answer)
► Much less than before phototherapy  2
► Slightly less than before phototherapy  1
► Comparable with before phototherapy  0
► Slightly more than before phototherapy  -1
► Much more than before phototherapy  -2
► Not relevant  0
7. To what extent does your skin nowadays restrain you from working or studying compared 
with before phototherapy?
(complete only one answer)
► Much less than before phototherapy  2
► Slightly less than before phototherapy  1
► Comparable with before phototherapy  0
► Slightly more than before phototherapy  -1
► Much more than before phototherapy  -2
► Not relevant  0
8. To what extent does your skin nowadays play a role when problems arise with friends or 
family compared with before phototherapy?
(complete only one answer)
► Much less than before phototherapy  2
► Slightly less than before phototherapy  1
► Comparable with before phototherapy  0
► Slightly more than before phototherapy  -1
► Much more than before phototherapy  -2
► Not relevant  0
9. To what extent does your skin nowadays play a role in sexual problems compared with before 
phototherapy??
(complete only one answer)
► Much less than before phototherapy  2
► Slightly less than before phototherapy  1
► Comparable with before phototherapy  0
► Slightly more than before phototherapy  -1
► Much more than before phototherapy  -2
► Not relevant  0
10. To what extent does your skin nowadays play a role in finding new friends and new 
relationships compared with before phototherapy??
(complete only one answer)
► Much less than before phototherapy  2
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► Slightly less than before phototherapy .....................................1
► Comparable with before phototherapy .....................................0
► Slightly more than before phototherapy .................................... -1
► Much more than before phototherapy ....................................-2
► Not relevant .................................................................... 0
11. To what extent do you nowadays feel stared at by people in your neighbourhood compared 
with before phototherapy??
(complete only one answer)
► Much less than before phototherapy .....................................2
► Slightly less than before phototherapy .....................................1
► Comparable with before phototherapy .....................................0
► Slightly more than before phototherapy .................................... -1
► Much more than before phototherapy ....................................-2
► Not relevant .................................................................... 0
12. To what extent does your skin nowadays lead to insecurity or negative feelings compared 
with before phototherapy?
(complete only one answer)
► Much less than before phototherapy .....................................2
► Slightly less than before phototherapy .....................................1
► Comparable with before phototherapy .....................................0
► Slightly more than before phototherapy .................................... -1
► Much more than before phototherapy ....................................-2
► Not relevant .................................................................... 0
13. To what extend does you skin nowadays influence your choice of clothes compared with 
before phototherapy?
(complete only one answer)
► Much less than before phototherapy .....................................2
► Slightly less than before phototherapy .....................................1
► Comparable with before phototherapy .....................................0
► Slightly more than before phototherapy .................................... -1
► Much more than before phototherapy ....................................-2
► Not relevant .................................................................... 0
14. How much time do you need camouflaging vitiligo lesions compared with before 
phototherapy?
(complete only one answer)
► Much less than before phototherapy .....................................2
► Slightly less than before phototherapy .....................................1
► Comparable with before phototherapy .....................................0
► Slightly more than before phototherapy .................................... -1
► Much more than before phototherapy ....................................-2
► Not relevant .................................................................... 0
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Chapter 5
5.1 Introduction
The aims of this thesis have been described in section 1.5 and comprise:
I. Further elucidation of the photobiological effects, in particular regarding 
photodamage of UVA, broadband UVB, narrowband UVB and visible light.
II. To find out to what extent anti-TNF-a treatment modulates the response to 
UVB challenge
III. To find out the clinical efficacy of narrow band UVB treatment in vitiligo and 
the impact of this treatment on quality of life.
In this chapter, the contributions will be summarised and the questions as formulated 
in the introduction will be answered.
5.2 Further elucidation of the photobiological effects, in particular 
regarding photodamage of UVA, broadband UVB, narrowband UVB 
and visible light.
5.2.1 What are the differences between the photobiological responses of 
UVA and UVB, especially with respect to oxidative processes?
As shown in chapter 2, UVA and UVB affect different photochemical pathways 
to induce photobiological responses. Generally, UVB exerts its effects by type I 
reactions, thereby directly damaging cell structures and molecules. UVA, on the 
other hand, exerts its effects by indirect type II reactions, mediated by reactive 
oxygen species (1). Although this hypothesis is generally accepted, no in vivo data 
were available to support this hypothesis. Recently however, Sander et al. showed 
that UVA induced oxidative products are associated with long-term effects of UVA 
exposure, such as photoageing (2 ).
In chapter 2 the photobiological and oxidative effects after a single exposure to UVA 
and UVB have been investigated. UVA and UVB both induce inflammation in the 
upper dermis, as shown by the increase in inflammatory infiltrate. This increase is 
most pronounced in UVB irradiated skin and is mainly attributed to an increase in 
T-cells. Although the used irradiation dose was quite low and did not result in the 
induction of sunburn cells, p53 and c-Jun expression were observed. P53 expression 
reached an earlier and higher expression in UVB compared to UVA irradiated skin. A 
similar expression pattern was seen for c-Jun; a statistically significant increase was 
reached 4 hour after UVB exposure and 24 hours after UVA irradiation.
With the performed non-invasive techniques it was possible to demonstrate a 
pronounced induction of oxidised lipids in UVA irradiated skin one hour after 
irradiation, as measured by squalene peroxide levels. This induction was significantly
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enhanced in UVA irradiated skin compared to UVB irradiated skin. Furthermore, 
catalase activity, an endogenous antioxidant system, was impaired by 80% 4 hours 
after irradiation with UVA. A previous study showed that UVB does not influence 
catalase activity (3).
The delay in expression of the p53 and c-Jun markers after UVA irradiation could be 
explained by the fact that p53 and c-Jun are induced by activation of the oxidative 
pathway (4,5). The results mentioned in chapter 2 support this hypothesis.
5.2.2 What are the differences between broadband and narrowband 
UVB induced photodamage?
Narrow band UVB is gradually replacing broadband UVB phototherapy and also 
PUVA photochemotherapy in Europe. There is, however, discussion on the safety 
aspect, as several experimental studies have shown increased photocarcinogenesis 
in mice (6 -8 ). As a higher dose of narrow band UVB is generally used over a shorter 
treatment period compared to broad band UVB phototherapy an enhanced and 
modified photobiological effect can be expected (9,10). This thesis shows that, an 8.1 
higher narrow band UVB dose is needed to induce erythema in the skin of healthy 
volunteers. Acute effects of broad band UVB are inflammation, characterised by a 
perivascular infiltrate consisting of T-lymphocytes, polymorphonuclear leukocytes, 
and a significant decrease of the number of epidermal Langerhans cell (11,12), as 
well as a pronounced induction of p53, p16 and sunburn cells (13-15). This thesis 
confirms previous findings and shows that similar effects are seen in 3 MED narrow 
band UVB irradiated skin. No differences were observed between the photobiological 
responses to 3 MED broad band and 3 MED narrow band UVB exposure. Thus, an 
equivalent erythematogenic dose induces a similar photobiological effect, although 
physical doses differ a factor 8.1. This observation seems to contradict the findings 
of the study by Sheehan et al. who showed that the photobiological effect depends on 
the physical dose and not on the biological dose as measured with MED (16). This 
discrepancy could be explained by the difference in wavelength spectrum, as the 
study described in chapter 2 focuses only on 311 nm wavelength, while the study by 
Sheehan et al focused on the whole UVA and B spectrum (295-400 nm) (17).
5.2.3 Is visible light capable of inducing photodamage?
Visible light has always been regarded as safe and harmless at natural exposure 
conditions. In the last decade high dose visible light applications, such as laser and 
photodynamic therapy (PDT), have been introduced in dermatology. Studies on the 
effects of high dose visible light are sparse. As discussed in chapter 2, PDT depends 
on the availability of specific chromophores in the treatment area. In practise, to treat
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target lesions with photodynamic therapy, it is necessary to increase the amount of 
locally available chromophores by applying 5-aminoleavulinic acid or derivatives (18). 
Chromophores such as DNA and bilirubin are naturally available in the skin (19,20). 
It is feasible that irradiation of these endogenous chromophores by high dose visible 
light, as used in PDT, could induce oxidation of surrounding molecules and lead to 
'adverse' photobiological effects, such as photocarcinogenesis and photoageing. With 
the emerging wide spread use of this presumably safe therapy, questions concerning 
its safety arise. The sparse investigations on photobiological effects of visible light 
usually include the near-UVA spectrum of light (400-500 nm). Several studies have 
shown that near-UVA irradiation results in UVA-like photobiological effects, such as 
DNA strand breaks due to singlet oxygen species. To a lesser extent p53 induction 
and immediate pigment darkening are observed (21-24). Edström et al. showed that 
high dose visible light (400-800 nm) may induce limited p53, Ki67 and p21waf 
expression (25,26). Their spectrum however did include the near-UVA range (27). 
Therefore, a significant near-UVA effect cannot be excluded. In contrast, the study 
described in chapter 2, on the effects of high dose long wave visible light (560-780 
nm) on skin of healthy volunteers, showed no induction of p53, c-Jun, Melan A, 
MMP-1 and sunburn cell formation. However, perinuclear vacuolisation was seen, 
which appeared 24 hours after the first irradiation, reached significance after the 4th 
irradiation, and did not return to normal one week after the last irradiation. So far, The 
significance of perinuclear vacuolisation is not clear. In UVB exposed skin a similar 
phenomenon can be observed. It could be hypothesised that this is a transitional stage 
toward apoptosis (28,29). In the study presented in chapter 2, no sunburn cells were 
seen for up to 11 days after the first irradiation and, as no p53 and c-jun expression 
was seen it is highly unlikely that an apoptosis pathway was induced.
5.3 To what extent does anti-TNF-a treatment modulate the 
response to UVB challenge?
5.3.1 What is the effect of anti-TNF-a treatment on the photobiological 
response after a single broad band UVB challenge?
TNF-a is a pro-inflammatory cytokine and has been shown to play a role in UV 
induced inflammation. It has been demonstrated that TNF-a expression is induced 
after UV irradiation (30,31). Anti-TNF-a has been introduced in the treatment of 
several chronic inflammatory diseases, such as rheumatoid arthritis, juvenile chronic 
arthritis, Crohn's disease and recently as experimental treatment in psoriasis vulgaris 
(32-35). It is remotely possible that single target therapies could potentially influence 
photobiological processes, such as photocarcinogenesis. In vitro studies have shown 
that suppression of the TNF-a photoresponse could reduce the expression of DNA
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damage markers and inhibit apoptosis (36-39). It is unknown if similar effects in vivo 
occur after treatment with anti-TNF-a and whether reduced apoptosis could implicate 
enhanced photocarcinogenesis.
The study described in chapter 3 investigates the effects of anti-TNF-a on the broad 
band UVB induced photoresponse, with focus on photodamage. Rheumatoid arthritis 
patients were irradiated with 2 MED broad band UVB, before and after treatment 
with anti-TNF-a.
In the epidermis a significant increase in p53, c-jun expression and apoptosis was 
seen after irradiation in the epidermis. A significant increase in dermal matrix 
metalloproteinase-1 (MMP-1) expression was observed in the dermis. After treatment 
with the anti-TNF-a antibody only significant changes were seen in the expression of 
c-Jun and phosphorylated c-Jun expression, which slightly but significantly decreased 
during treatment with anti-TNF-a compared to before anti-TNF-a treatment. The 
production of matrix metalloproteinases is closely associated to the expression 
of c-Jun (40). In the study described in chapter 3 however, no change in MMP-1 
expression before and after anti-TNF-a treatment was seen.
As mentioned earlier, in vitro anti-TNF-a can reduce photodamage and apoptosis. 
Our study shows that in vivo this effect is not expressed. We cannot exclude with 
certainty that a reduction might have been observed if a different time schedule was 
chosen, as the pharmacokinetics of the antibody in the skin is still largely unknown.
5.4 What is the clinical efficacy of narrow band UVB treatment in 
vitiligo and the impact of this treatment on quality of life?
5.4.1 Is narrow band UVB an effective treatment for vitiligo vulgaris?
Narrow band UVB has been introduced a few years ago as a possibly new and safe 
alternative for PUVA in the treatment of vitiligo (41-43). With the knowledge that 
photo (chemo)therapy for vitiligo is usually an intensive and protracted treatment 
and that especially long-term photochemotherapy may increase the risk of skin 
cancer significantly, a safe new and effective treatment is needed (44,45). Studies 
on the efficacy of narrow band UVB are sparse. These studies often use inaccurate 
graded scoring methods such as less than 25%, 26-50%, 51-75% and 76-100%) 
(46,47). These scoring methods evaluate repigmentation over the whole body and 
these methods do not reconcile the fact that the repigmention rate differs per body 
area and that some areas show complete repigmentation and some do not repigment 
at all. The study in chapter 4 describes a new repigmentation scoring system, which 
describes repigmentation percentage per body area. In this open study twenty-seven 
patients with long-term stable vitiligo (at least one year no new lesions or growth of 
vitiligo lesions) were irradiated thrice weekly with narrow band UVB phototherapy.
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Irradiation dosages were increased on an individual basis with 0-30%. The percentage 
of repigmentation was estimated per body area. Areas with maximum repigmentation 
rate were designated as 'maximum repigmentation'.
This study clearly showed that narrow band UVB phototherapy is an effective 
treatment for vitiligo and that at least in one or more body areas in 92% of the patients 
up to 100% repigmentation could be reached. Furthermore it showed that 'hairless' 
lesions, such as dorsa of hands (knuckles and fingers), the inner wrist and feet, almost 
do not repigment (median repigmentation 22.5%), while other areas such as extensor 
surfaces of the lower arm and leg, back and throat often repigment rather easily 
(up to 100%). With these results in mind a revision of the generally used vitiligo 
repigmentation scoring methods seems warranted.
5.4.2 Does the addition of vitamin B12 and folic acid modulate the 
efficacy of narrow band UVB phototherapy in the treatment of vitiligo 
vulgaris?
Several authors have suggested that deficiencies, at the cellular level, of biochemical 
compounds, such as pseudocatalase, calciumchlorid and phenylalanine, which play 
a part in the melanogenesis pathway, could play a role in the pathogenesis of vitiligo 
(48-50). Some studies have shown that addition of these compounds could improve 
the repigmentation efficacy of phototherapy (48,51,52). In several groups of vitiligo 
patients, vitamin B12 and folic acid deficiencies have been demonstrated, although 
this is not a common characteristic to all vitiligo patients (53,54).
Although vitamin B12 and folic acid are not directly part of the melaninsynthesis 
pathway, indirect influence on the melaninsynthesis is likely (55). The combination 
of vitamin B12 and folic acid with UV exposure has been tested before in the 
sunny regions of Sweden (56). In this study a clear repigmentation was seen in 
vitiligo patients. This study however did not include a control group and did use 
a non-standardised irradiation protocol, i.e. expose the skin as much as possible to 
the Swedish sun. In the study mentioned in chapter 4, twenty-seven patients were 
randomised for treatment with narrow band UVB in combination with vitamin B12 
and folic acid or treatment with narrow band only. Both groups were irradiated thrice 
weekly with narrow band UVB in our clinic. Although clear repigmentation was 
observed, no difference was seen between both groups.
5.4.3 Does long-term narrow band UVB phototherapy influence the 
quality of life in patients with vitiligo vulgaris?
Although vitiligo is not life threatening or physical debilitating, it is a very visible and 
socially handicapping disease as the lesions have as predilection sites the hands and
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face, which can negatively influence quality of life (57-60). Studies on the efficacy 
of treatments for vitiligo vulgaris have always been focused on the effectiveness of 
therapies on repigmentation, whereas quality of life studies are sparse.
Assessment of quality of life may provide relevant information on the actual benefit 
of a treatment in patients with chronic diseases such as vitiligo. Quality of life 
research in vitiligo has mostly been focused on the impact of vitiligo on social, 
psychological and physical wellbeing and less on the impact of therapies on these 
factors (57,58,61,62). Quality of life problems in vitiligo patients can be categorised 
in the following categories: choosing clothes, use of sunblocks, use of camouflage, 
avoidance of activities, reactions of others and emotional reactions (57,58). There 
is no specific vitiligo oriented quality of life index. Njoo et al. studied the quality 
of life in children with vitiligo with the Child Dermatology Life Quality Index, a 
revised version of the 'adult' Dermatology Life Quality Index (DLQI) developed by 
Finlay and Khan (63). For the study in patients with vitiligo described in chapter 4 a 
slightly revised version of this DLQI was devised with more focus on visibility and 
avoidance. Furthermore, the questions were modified in view of the retrospective 
character of the study. A high percentage of the invited participants responded 
(71.4%), which is exceptionally high compared with the response rate of 39% in 
another quality of life questionnaire in vitiligo patients (57,58). This can be explained 
by the fact that all patients had recently finished long term phototherapy for vitiligo, 
with high compliance, while in the study by Kent and Al-Abadie all members of the 
UK vitiligo society, with or without current or recent treatment were invited (57,58). 
The response rate in our study was similar to that of other vitiligo studies where all 
patients were currently under active treatment (64).
Although our study used a non-validated retrospective Quality of Life Questionnaire, 
several interesting results were found. After long-term phototherapy for vitiligo, 
skin appearance does not play a major role in the lives of vitiligo patients anymore 
(as indicated by reduced feelings of insecurity and negative feelings) although only 
in a minority of patients general well-being improved. Furthermore, phototherapy 
increased the necessity to camouflage of the lesions, due to the pigment darkening 
of the surrounding uninvolved skin. The limited improvement of well-being and 
the increased necessity for camouflage seriously restricts our enthousiasm on the 
relevance of phototherapy in vitiligo. Long-term prospective studies are warranted to 
evaluate long-term effects on quality of life.
5.5 Future suggestions
Based on the findings and discussions in this thesis several suggestions for further 
research can be made.
The delay in UVA photoresponse compared to UVB, as described in chapter 2.1 
might be caused by oxidative damage. Further studies should test this hypothesis.
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As discussed before, the therapeutic efficacy of narrow band UVB is reached 
earlier as compared to broad band UVB, after treatment with doses with equivalent 
erythematogenic effects. However, the physical doses of narrow band UVB as 
compared to broad band UVB are substantially higher before a similar therapeutic 
effect is reached. The study in chapter 2.2 showed that narrow band and broad band 
UVB in equivalent erythematogenic doses after a single challenge have similar 
photodamage profiles. This supports the hypothesis that narrow band UVB is the 
safer treatment. However, repeated exposure and long term studies are necessary to 
further substantiate this hypothesis.
As described in chapter 2.3 high dose visible light seems safe, but it is unknown why 
perinuclear vacuolisation occurs. Long-term studies could provide more information 
on the significance of this phenomenon.
Based on the discussion in chapter 3 further studies on the effect of anti-TNF-a on 
photocarcinogenesis should be performed. In the present study we have restricted 
our observation to the effects in the skin 2 weeks after anti-TNF-a treatment. It is 
remotely possible that anti-TNF-a might have more acute or even delayed effects on 
the responses to UV. Further studies should clarify this issue.
As discussed in chapter 4.1 further development of a new more reliable scoring 
method for repigmentation efficacy, based on regional differences in repigmentation, 
is necessary.
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Chapter 6
6.1 Nederlandse samenvatting en conclusies
In dit proefschrift werden de effecten van diverse lichtspectra op de normale huid 
onderzocht alsmede de effectiviteit van smalspectrum UVB als behandeling voor 
vitiligo.
Hiervoor werden in de inleiding (hoofdstuk 1) een aantal vragen geformuleerd, welke 
in hoofdstuk 2, 3 en 4 werden beantwoord aan de hand van originele artikelen.
In hoofdstuk 2 werden de fotobiologische responsen van diverse lichtspectra 
onderzocht. Er is met name gekeken naar huidveroudering en beschadiging onder 
invloed van licht, maar ook naar inflammatie en pigmentatie. In paragraaf 2.1 worden 
breedspectrum UVA en UVB met elkaar vergeleken met nadruk op verschillen in 
oxidatieve processen en mogelijke relaties met huidbeschadiging en inflammatie. 
Er wordt al geruime tijd verondersteld dat UVA met name via oxidatieve processen 
effecten induceert. UVB veroorzaakt een direct effect. De gebruikelijke en verwachte 
expressiepatronen van inflammatie- en huidbeschadigingsparameters werden gezien. 
Opvallend was een vertraging van ongeveer 3-20 uur in de expressie van p53 en c- 
Jun na UVA belichting ten opzichte van UVB belichting. UVA induceerde significant 
meer oxidatieve schade (gemeten aan de hand van catalase verbruik en lipid 
oxidatie) dan UVB, welke al een uur na de UV blootstelling gemeten kon worden. 
Een uur na UVA blootstelling werd al een 882% stijging in squaleen hydroperoxide 
waargenomen tegenover een slechts 111% stijging in UVB blootgestelde huid. Een 
anti-oxidant systeem als catalase liet daarentegen een uur na UVA blootstelling al een 
70% daling in activiteit zien, welke zich niet binnen 48 uur herstelde. Dit fenomeen 
werd niet bij UVB waargenomen. Gezien deze bevindingen is het waarschijnlijk dat 
de vertraging in p53 en c-Jun expressie aan deze oxidatieve processen kan worden 
toegeschreven.
In paragraaf 2.2 werden twee spectra van UVB met elkaar vergeleken, namelijk 
smalspectrum (311 nm) en breedspectrum (290-320). Ook hier werden 
huidbeschadiging, veroudering en inflammatie na UV blootstelling bestudeerd. Alle 
vrijwilligers werden aan 3x de minimale erytheemdosis (MED) blootgesteld. De 
fysische dosis voor één MED was gemiddeld een factor 8  hoger bij de smalspectrum 
UVB groep. Desondanks bleek dat ondanks dit grote verschil vergelijkbare expressie 
van markers voor huidbeschadiging, veroudering en inflammatie werden gezien. 
Er waren geen statistisch significante verschillen tussen beide groepen. Met de 
wetenschap dat smalspectrum UVB klinisch veel effectiever is gebleken in de 
behandeling van eczeem en psoriasis en dat over het algemeen minder belichtingen 
nodig zijn, kan worden geconcludeerd dat smalspectrum UVB lichttherapie hierdoor 
mogelijk ook veiliger is dan breedspectrum UVB.
In de afgelopen jaren worden hoge doses zichtbaar licht in toenemende mate toegepast 
in de dermatologie, onder andere in het kader van de fotodynamische therapie. In
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paragraaf 2.3 werd gekeken naar de mogelijke effecten van hoge doses zichtbaar licht 
op de normale huid. Zichtbaar licht werd altijd als volledig onschadelijk betracht. 
Echter diverse studies hebben aan getoond dat er wel degelijk expressie van diverse 
huidbeschadigings- and verouderingsmarkers geïnduceerd konden worden. Met de 
studie beschreven in paragraaf 2.3 lieten wij zien dat deze bevindingen enigszins 
genuanceerd moeten worden. Met het zichtbaar licht spectrum (560-700 nm), 
zoals gebruikt in deze studie, werd alleen het onbekende fenomeen perinucleaire 
vacuolisatie gezien. Er werden geen andere markers tot expressie gebracht. De eerder 
beschreven veranderingen onder zichtbaar licht lijken te worden bewerkstelligd 
door het deel van het zichtbaar licht spectrum dat nog vrij energierijk is en dicht bij 
het UVA spectrum ligt (400-560 nm). In het gebruikte spectrum van deze vorm van 
fotodynamische therapie leek er geen relevante schade aan de omringende huid te 
worden toegebracht gedurende enkele of meerdere PDT-sessies. De relevantie van de 
perinucleaire vacuolisatie is onduidelijk.
In hoofdstuk 3 werd aandacht besteed aan de mogelijke beïnvloeding van de 
lichtrespons door anti-TNF-a, een nieuw geneesmiddel voor chronisch inflammatoire 
aandoeningen als reumatoïde artritis en M.Crohn. Inmiddels wordt deze therapie ook 
in trialverband binnen de dermatologie toegepast. Aangezien TNF-a een belangrijke 
pro-inflammatoire factor is in de UV-respons, leek het zinvol om de invloed van dit 
geneesmiddel op de UV-respons te onderzoeken. In het kader van een onderzoek bij 
patiënten met chronisch reumatoïde artritis werden patiënten, voor en na toediening 
van anti-TNF-a, aan UVB blootgesteld. De klinische effectiviteit van een subcutane 
injectie met anti-TNF-a, op het synovium van reumatoïde artritis patiënten, is na 2 
weken optimaal. Daarom was er voor gekozen om de respons op UVB bestraling 2 
weken na de toediening van anti-TNF-a te onderzoeken. In dit tijdschema werden 
behoudens een minimale maar significante toename in c-Jun expressie geen andere 
verschillen waargenomen. Het is niet uit te sluiten, dat een gewijzigd tijdschema, 
met het biopt kort na de subcutane toediening van het anti-TNF-a antilichaam, wel 
effecten op beschadigingsmarkers kan laten zien.
In hoofdstuk 4 werd gekeken naar de klinische en psychosociale effecten van 
smalspectrum UVB lichttherapie voor de behandeling van vitiligo. Tot voor kort 
was PUVA fotochemotherapie de behandeling bij uitstek voor vitiligo. Met de komst 
van smalspectrum UVB lijkt hier verandering in te komen. Recent onderzoek heeft 
aangetoond dat smalspectrum UVB een effectieve therapie voor vitiligo lijkt te 
zijn. Het grote nadeel van deze onderzoeken was het feit dat er onnauwkeurige en 
algemene scoringsmethodes gebruikt werden. Effectiviteit werd namelijk gemeten 
in vier repigmentatie gradaties (minder dan 25%, 26-50%, 51-75% en 76-100%), 
welke gelden voor het gehele lichaam. In de studie in paragraaf 4.1 werd rekening 
gehouden met regionale verschillen in repigmentatie. Dit onderzoek liet zien dat
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3 keer per week smalspectrum UVB lichttherapie in 92% van de patiënten tot een 
volledige repigmentatie van diverse laesies kon leiden en dat diverse 'haarloze' 
laesies als handen, binnenzijde van de polsen en voeten slechts minimaal (<2 0 %) 
repigmenteerden.
Diverse auteurs hebben aangetoond dat het toevoegen van stoffen, die een mogelijke 
rol bij de melanogenese spelen, in combinatie met lichttherapie tot een versnelde en 
verbeterde repigmentatie zou kunnen leiden. De studie in paragraaf 4.1 onderzocht 
de effecten van vitamine B12 en foliumzuur op smalspectrum UVB geïnduceerde 
repigmentatie. Enkele studies hadden aangetoond dat sommige patiënten een 
deficiëntie voor vitamine B12 en foliumzuur hebben en dat zonlichtblootstelling 
in combinatie met suppletie effectief zou zijn. Uit onze studie bleek er echter geen 
significant verschil met de controle groep te zijn in repigmentatie effectiviteit. 
Ondanks dat vitiligo geen levensbedreigende of lichamelijk invaliderende ziekte 
is hebben veel patiënten, door de zichtbaarheid van de aandoening, regelmatig 
psychosociale problemen. De effectiviteit van lichttherapie wordt voornamelijk 
gemeten aan de hand van de repigmentatie en slechts zelden aan verbetering 
van de kwaliteit van leven. In de studie beschreven in paragraaf 4.2 werden alle 
vitiligopatiënten die in de periode 1998-2001 langdurig met smalspectrum UVB 
lichttherapie werden behandeld, gevraagd deel te nemen aan een kwaliteit van 
leven vragenlijst. Hierbij bleek dat de meeste patiënten sinds de behandeling 
minder aandacht aan hun huid en huidaandoening schonken, maar ook dat er in 
sommige gevallen meer gecamoufleerd moest worden. Dit valt te verklaren door 
een toegenomen contrast tussen gepigmenteerde en gedepigmenteerde huid na 
lichttherapie en het feit dat de handen voorkeurslokalisaties zijn en minder goed 
repigmenteren (zie paragraaf 4.1).
In hoofdstuk 5 werden alle bevindingen samengevat en bediscussieerd aan de hand 
van de bestaande literatuur.
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Dankwoord
Dit proefschrift had niet tot stand kunnen komen zonder de samenwerking en hulp 
van velen. Helaas is het onmogelijk om iedereen die een bijdrage heeft geleverd bij 
naam te noemen. Op deze waarschijnlijk meest gelezen pagina’s van het proefschrift 
zal ik een poging doen om de belangrijksten te vermelden.
Allereerst natuurlijk mijn promotor professor Peter van de Kerkhof. Zonder uw 
leiding en drijfkracht had dit proefschrift nooit vorm gekregen. U ontving mijn 
soms wel wat ongebruikelijke en soms ‘alternatieve’ onderzoeksvoorstellen met 
enthousiasme en creëerde ook de mogelijkheid om deze dan ook daadwerkelijk tot 
uitvoering te brengen. De snelheid en zorgvuldigheid waarmee u mijn ideeën en 
artikelen bestudeerde en zonodig corrigeerde blijft me verbazen.
Rianne Gerritsen, als mijn co-promotor schreef jij grote delen van de projecten 
die uiteindelijk tot dit proefschrift hebben geleid. Ook jij stond open voor allerlei 
ideeën die tot diverse publicaties hebben geleid. Voor alle problemen, al dan niet 
proefschriftgerelateerd, kon ik altijd bij je terecht. Je verbaasde me aangenaam door 
actief deel te nemen aan een cursus behandeling van psoriasis met Chinese kruiden in 
Londen, iets wat ik altijd zal blijven onthouden.
Marisol Kooijmans-Otero, zonder jou is klinisch onderzoek op de afdeling nauwelijks 
mogelijk. Voor al je hulp, ideeën en vriendschap wil ik je hartelijk bedanken. Het is 
trouwens maar goed dat kamer 2 geen oren heeft. Iedereen kon altijd zijn hart bij je 
komen luchten of even lekker komen 'roddelen'.
Jaappieter Wolffensperger, je was mijn eerste wetenschappelijk stage student. Voor 
beiden wel even wennen, maar je hebt prachtig werk geleverd (cum laude) en ik hoop 
dat het leven als legerarts je goed is bevallen.
Tim Smits, aanvankelijk begonnen als wetenschappelijk stagiaire (cum laude) 
en nu zelf promovendus op onze afdeling dermatologie. Je enthousiasme en 
wetenschappelijke inzicht kwamen nog net op tijd voor mij, en brachten mijn 
promotie in de noodzakelijke stroomversnelling. Iets wat uiteindelijk resulteerde 
in een langdurige samenwerking, hechte vriendschap en meerdere publicaties en 
presentaties.
Lieve Declerq en Lieveke Hellemans, jullie hebben mijn kijk op de cosmetische 
industrie grondig gewijzigd. Ook jullie dank ik voor de prettige wetenschappelijke 
samenwerking.
Jürgen, als kamergenoot en mede-promovendus, hartelijk dank voor je vriendschap, 
de gezelligheid en de vele uren die we al prettig kibbelend over zakcomputers samen 
hebben doorgemaakt.
Arno en Wijnand, jullie zijn beiden langere tijd kamergenoten geweest. Met jullie is 
onze oorspronkelijke meidenkamer (Astrid, Mieke en Mai Le) toch echt een gezellige
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Alfons den Broeder, ja het heeft even geduurd, maar eindelijk zit ook mijn promotie 
erop.
Gijs, je kennis van de statistiek is indrukwekkend, zeker voor een statistische leek 
als ik. Jij stond altijd klaar om me verder te helpen. Waar was ik ook zonder je 
gebleven.
Natuurlijk moet ik Mieke, Ivonne en Candida bedanken, voor alles wat jullie me 
geleerd hebben over immunohistochemie en werken op het lab. Jullie hulp was 
onmisbaar.
Mijn collega-AGIO’s en -AGNIO’s Han, Conrad, Monique, Carine, Marieke, Astrid, 
Rob, Roland, Fransje, Quintus, Mandy, Martina, Maurice, Manon, Saskia en José, 
met jullie heb ik de afgelopen jaren in wisselende samenstelling zeer prettig en 
gezellig gewerkt, hiervoor bedankt.
Patrick, Bas, Rolf, Mirjam, Fred, Wendy, Leon, Michel, Manon en Reno, jullie en 
anderen zijn sfeerbepalend geweest op het lab en hebben mij mijn tijd daar als zeer 
prettig doen ervaren.
Alle stafleden, secretaresses, fotografen, administratief en verplegend personeel wil 
ik zeker niet vergeten. Hartelijk dank voor al jullie hulp en belangstelling.
Mijn ouders, schoonouders, Marvin, Audrey, Sioe Hoey, Bertram, Sioe Kian, René, 
Yiu Loon, Hidde, John en vele andere vrienden en familie, jullie wil ik bedanken voor 
al jullie onvoorwaardelijke steun, liefde en vriendschap die jullie mij de afgelopen 
jaren hebben gegeven.
Sioe Lie, mijn lieve vrouw, steun en toeverlaat, last but not least wil ik ook jou 
bedanken voor al je hulp, support en geduld.
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